WO2004084747A2 - Apparatus and method for optimizing tumor treatment efficiency by electric fields - Google Patents

Apparatus and method for optimizing tumor treatment efficiency by electric fields Download PDF

Info

Publication number
WO2004084747A2
WO2004084747A2 PCT/IB2004/000918 IB2004000918W WO2004084747A2 WO 2004084747 A2 WO2004084747 A2 WO 2004084747A2 IB 2004000918 W IB2004000918 W IB 2004000918W WO 2004084747 A2 WO2004084747 A2 WO 2004084747A2
Authority
WO
WIPO (PCT)
Prior art keywords
electric field
electrodes
cells
electrode
insulated
Prior art date
Application number
PCT/IB2004/000918
Other languages
French (fr)
Inventor
Yoram Palti
Original Assignee
Standen Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/204,334 external-priority patent/US7333852B2/en
Application filed by Standen Ltd. filed Critical Standen Ltd.
Publication of WO2004084747A2 publication Critical patent/WO2004084747A2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/0404Electrodes for external use
    • A61N1/0472Structure-related aspects
    • A61N1/0484Garment electrodes worn by the patient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/0404Electrodes for external use
    • A61N1/0408Use-related aspects
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/0404Electrodes for external use
    • A61N1/0472Structure-related aspects
    • A61N1/0492Patch electrodes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/326Applying electric currents by contact electrodes alternating or intermittent currents for promoting growth of cells, e.g. bone cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36014External stimulators, e.g. with patch electrodes
    • A61N1/36021External stimulators, e.g. with patch electrodes for treatment of pain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36071Pain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/40Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals

Definitions

  • the present invention relates to the selective destruction of rapidly
  • microorganisms such as bacteria, mycoplasma, yeast, protozoa, and other
  • Dividing cells of organisms can be destroyed, or their proliferation controlled, by methods that are based on the
  • centrioles each cell contains 2 being moving towards opposite poles of the cell.
  • each chromosome is composed of duplicate chromatids.
  • Microtubular spindles radiate from regions adjacent to the centrioles, which are
  • chromosomes move toward the equator of the cell and align in the equatorial plane.
  • the cell begins to elongate along the axis of the pole; the pole-to-
  • Late anaphase occurs when the daughter chromosomes (as
  • cytokinesis begins as the cleavage furrow begins to form at the equator of the cell.
  • late anaphase is the point at which pinching the cell membrane
  • telophase begins. During telophase, cytokinesis is nearly complete and spindles disappear.
  • the cell undergoes a second division, involving separation
  • cancer treatments e.g., irradiation therapy and the use of various chemo-therapeutic
  • Such treatments are based on the fact that cells undergoing division are
  • cancer treatments typically cause significant damage to normal tissues, thus limiting
  • Examples of the first type of application include the following: cardiac
  • defibrillators peripheral nerve and muscle stimulators, brain stimulators, etc.
  • an electric wave such as an RF wave or a microwave source that is directed at the
  • the applied electrical current destroys substantially all cells in the
  • fields can be separated into two types, namely (1) steady fields or fields that change
  • the electric fields are high frequency alternating
  • the first type of electric field is used, for example, to stimulate
  • CNS central nervous system
  • the recording of such natural fields is the basis for the ECG, EEG, EMG,
  • This heating can be calculated by the power dissipated in the tissue
  • stimulatory power on nerve, muscle, etc.
  • is an inverse function of the frequency
  • one negative effect is the changes in ionic concentration in the various
  • [Ca ++ ] in the extracellular fluid is about 2 x 10 "3 M,
  • the ions depends on the current intensity ion mobilities, membrane ion conductance,
  • the dominant field effect is that due to dielectric losses and
  • an electric field is applied for targeting selected cells to
  • the cells are selected on the basis of intrinsic or induced differences in a characteristic
  • electroporation threshold The differences in this threshold can depend upon a number of parameters, including the difference in cell size.
  • the method of the '066 patent is therefore based on the assumption
  • the size difference between normal cells and tumor cells is
  • the voltages which are applied may damage some of the normal cells and may not ⁇
  • dielectric properties may vary significantly.
  • the data regarding the specific tumor can be provided by conventional techniques, such as
  • CT computed tomography
  • MRI magnetic resonance imaging
  • imaging of the tumor and its ' surroundings as well as other means
  • isolects are directly applied to the patient or by means of probes or pieces of
  • the apparatus can
  • cell may also refer to
  • organisms fungi, algae, mold
  • plants as or parts thereof that are not normally
  • the method of the present invention enables selective
  • selective destruction of living tissue is performed by inducing a non-homogenous electric field in the cells, as described below.
  • telophase This cleavage furrow is a slow constriction of the cell membrane
  • the cell structure is basically that of two sub-cells interconnected by a narrow
  • Such cells including first
  • organelles and macromolecules are polarizable, they are all force towards the bridge
  • the field polarity is irrelevant to the direction of the force
  • organelles have a "hammering" effect, whereby force pulses (or beats) are applied
  • organelles to the organelles numerous times per second, enhancing the movement of organelles
  • organelles themselves and may collapse or break the organelles.
  • the apparatus for applying for applying
  • the electronic apparatus includes a generator that generates an alternating voltage waveform at frequencies in the range
  • the generator is operatively connected to conductive leads which are connected at their other ends to insulated
  • the generator may provide each electrode with a specific
  • Fig. 1A-1E are simplified, schematic, cross-sectional, illustrations of
  • Figs. 2A and 2B are schematic illustrations of a non-dividing cell
  • Figs. 3 A, 3B and 3C are schematic illustrations of a dividing cell
  • Fig 4 is a schematic illustration of a dividing cell at one stage being
  • Fig. 5 is a schematic block diagram of an apparatus for applying an electric field according to one exemplary embodiment for selectively destroying
  • Fig. 6 is a simplified schematic diagram of an equivalent electric
  • Fig. 7 is diagrammatic flow chart for computing an optimal electric
  • Fig. 8 is a front elevation view of an undershirt incorporating the
  • present apparatus being worn over a human body
  • Fig. 9 is a cross-sectional taken along the line 9-9;
  • Fig. 10 is schematic view of a target area on which the electric field
  • Fig. 11 is a photographic image of the optimal position of electrodes
  • Fig. 12 is a schematic illustration of a geometric model for
  • Fig. 13 is an enlarged schematic illustration of one electrode of the
  • Fig. 14 is a photographic image of a resulting electric field generated
  • Fig. 15 is a schematic illustration representing the electric field of Fig. 14 by arrows;
  • Fig. 16 is a schematic illustration of a geometric model for
  • Fig. 17 is a photographic image of a resulting electric field generated
  • Fig. 18 is a schematic illustration representing the electric field of
  • Fig. 19 is a cross-sectional illustration of a skin patch incorporating
  • Fig. 20 is a cross-sectional illustration of the insulated electrodes
  • Fig. 21 is a cross-sectional illustration of the insulated electrodes
  • Figs. 22A-22D are cross-sectional illustrations of various components
  • Fig. 23 is a front elevation view in partial cross-section of two
  • insulated electrodes being arranged about a human torso for treatment of a tumor
  • a tumor associated with lung cancer e.g., a tumor associated with lung cancer
  • Figs. 24A-24C are cross-sectional illustrations of various insulated electrodes with and without protective members formed as a part of the construction
  • Fig. 25 is a schematic diagram of insulated electrodes that are
  • Fig. 26 is a cross-sectional view of insulated electrodes incorporated
  • intra-cranial tumor or the like
  • Fig. 27 is a partial section of a hat according to an exemplary
  • Fig. 28 is a cross-sectional view of the hat of Fig. 27 placed on a
  • Fig. 29 is a cross-sectional top view of an article of clothing having
  • Fig. 30 is a cross-sectional view of a section of the article of clothing
  • FIG. 29 illustrating a biasing mechanism for biasing the insulated electrode in a
  • Fig. 31 is a cross-sectional view of a probe according to one embodiment for being disposed internally within the body for treating a tumor or the
  • Fig. 32 is an elevation view of an unwrapped collar according to one
  • Fig. 33 is a side elevation view of the present apparatus being used to
  • Fig. 34 is an enlarged view of a stent used in the arrangement of Fig.
  • FIG. 1A shows a cell 10 at its normal
  • IB-ID show cell 10 during different stages of its division process, which results in
  • sub-cells 14 and 16 which eventually evolve into new cells 18
  • cell material cytoplasm surrounded by cell membrane
  • Cell 10 includes intracellular organelles,
  • Electrodes 28 e.g. , a nucleus 30. Alternating electrical potential is applied across electrodes 28
  • volume conductor consisting mostly of electrolytic inter-cellular
  • FIG. 2B depicted generally in Fig. 2B.
  • intercellular (i.e., extracellular) fluid and the intracellular fluid have a relatively low
  • the electric field lines (or
  • induced currents penetrate cell 10 from a portion of membrane 11 closest to one of
  • the electrodes generating the current e.g., closest to positive electrode 28 (also
  • source referred to herein as "source"
  • negative electrode 32 also referred to
  • electrodes 28 and 32 are electrically insulated.
  • insulated for insulated
  • non-insulated electrodes may be used efficiently in conjunction with the present
  • insulated electrodes have the advantage of lower power consumption and causing less heating of the treated regions.
  • the electric fields that are used in the present apparatus are alternating fields having frequencies that in the
  • TC fields which is an abbreviation of "Tumor Curing electric
  • intercellular fluid is mostly an electrolyte with a specific resistance of about 40-100
  • the cells are characterized by three elements,
  • cytoplasm that is mostly an electrolyte that contains numerous macromolecules
  • micro-organelles including the nucleus; and (3) membranes, similar in their electric
  • Fig. 2 schematically depicts the resulting field distribution in the
  • membrane is that of a resistor and capacitor in parallel, the impedance is function of
  • neck 22 (also referred to as "neck” 22) and, thus, the current/field line density within neck
  • intracellular organelles for example, nuclei 24 and 26 of sub-cells 14 and 16,
  • nuclei 24 and 26 are always in the direction of bridge 22.
  • dielectrophoresis intracellular organelles
  • intracellular organelles at a desired rhythm, e.g., a pre-selected number of times per
  • microtubule spindle that plays a
  • a dividing cell 10 is illustrated, at an
  • fields e.g., alternating fields in the frequency range of about lOOKHz to about
  • the lines 120 are microtubules that are known to have a
  • This structure forms sets of double dipoles and therefore, they are susceptible
  • conductive electrodes are used, i.e. , ion concentration changes in the cells and the
  • Fig. 5 is a simple schematic diagram of the electronic apparatus 200
  • the electronic apparatus 200 generates
  • TC signals desired electric field signals
  • the apparatus 200 includes a generator 210 and a set of pairs of conductive
  • ends of the leads 220 are connected to the insulated conductors 230 that are
  • the insulated conductors 230 are activated by the electric signals (e.g., waveforms).
  • the insulated conductors 230 are activated by the electric signals (e.g., waveforms).
  • the apparatus 200 includes a temperature sensor 240 or
  • the generator 210 generates multiple alternating voltage waveforms
  • the controller 300 is a programmable unit, such as a personal computer, or a personal computer.
  • the controller 300 is a programmable unit, such as a personal computer, or a personal computer.
  • controller 300 will then make the necessary computations.
  • the controller 300 also knows which
  • control box 250 When the control box 250 is included, it controls the outputs of the
  • the controller 300 issues a warning or the like when the
  • temperature (sensed by temperature sensor 240) exceeds a preset limit.
  • ⁇ VA A/(A+B+C+D+E).
  • the potential drop is on the capacitor (that acts as an insulator).
  • the capacitor practically is a short and therefore, practically all the
  • the impedance of the capacitors is to be decreased (i.e., increase their impedance
  • the isolects 230 are
  • TC fields can be applied by external isolects and second, the TC fields.
  • TC fields can be applied by internal isolects.
  • insulation can be replaced by very high dielectric constant insulating materials, such as
  • the dielectric constant can reach values of about
  • lithium nibate LiNbO 3
  • LiNbO 3 ferroelectric crystal
  • YIG is a ferrimagnetic crystal and magneto-optical devices, e.g., optical isolator
  • barium titanate (BaTiO 3 ) is a ferromagnetic
  • potassium tantalate which is a
  • LiTa ⁇ 3 which is a ferroelectric crystal with similar properties as lithium niobate
  • the isolects 230 can be shaped so
  • a gel such as a gel, that has high conductance and a high effective
  • the shaping can be pre-structured
  • the gel can be made of hydrogels, gelatins, agar,
  • thickness of the gel is not important so long as it is of sufficient thickness that the
  • the gel layer does not dry out during the treatment.
  • the gel layer does not dry out during the treatment.
  • thickness of the gel is about 0.5 mm to about 2 mm.
  • the isolects insulating material should be any material and field parameters. The isolects insulating material.
  • electrode 230 and its surroundings should be made of materials that facilitate heat
  • a coupling agent such as a conductive gel
  • the coupling agent is
  • a uniform layer of the agent disposed on the insulated electrode 230 and preferably, a uniform layer of the agent
  • the patient removes the units 540 so that the coupling agent
  • the leads 220 are standard isolated conductors with a flexible metal
  • the isolects 230 have specific shapes and positioning so
  • the number of electrodes 230 can typically be about 20-100, placed about 4-12 cm apart.
  • the electrodes 230 can be positioned individually on the skin, etc. , (as by an
  • adhesive or be part of an article of clothing, such as elastic undershirt, as
  • Each isolect 230 is illustrated in Figs. 8-9, that holds the electrodes in place.
  • Each isolect 230 is illustrated in Figs. 8-9, that holds the electrodes in place.
  • Electrode is connected to the controller 300 and is provided with a voltage signal
  • the method includes the general steps of
  • the user inputs different types of information that is used to compute the
  • the user inputs characteristics of
  • the tissue cells in the area to be treated at step 410, the user inputs characteristics of the tumor cells to be treated; and at step 420, the user inputs the anatomy of the area
  • this inputted information is used to compute the necessary field intensity in the tumor.
  • step 450 the maximal allowed field intensity at the various areas is
  • the number of isolects is preferably reduced in step 480 to
  • the function generating system e.g., the generator that
  • step 470 produces the waveforms mentioned in step 470, such as an analog wave generator or
  • a digital one e.g., a waveform generated by a PC and outputted through a digital to
  • isolects is monitored at step 510 and any errors are corrected. If any errors or
  • the field is modified as necessary according to the
  • a computation can be performed, for example, for the simple case; an isolect placed
  • isolect radius including coating ⁇ at and ⁇ muscie are the dielectric constants of the
  • the controller 300 calculates the TC field, using
  • the optimal map is sought. In other words, one optimizes the correlation between
  • the references include Fletcher, R. and
  • the undershirt 600 can be of an oversized type in that, as illustrated,
  • the undershirt 600 extends below the waist of the patient and in fact, it protrudes
  • the undershirt 600 can be of a more conventional type that lies above the waist.
  • the undershirt 600 has a predetermined number of electrodes 230 (e.g. , 20-100 in
  • the electrodes 230 are held
  • the undershirt construction in place by the undershirt construction, e.g., by adhesives or by stitching, etc.
  • the electrodes 230 completely extend radially around the body of
  • a model is constructed for a human having four electrodes around the mid
  • the axis units are in millimeters and the body is 0.5m width with a
  • FIG. 12 shows the location of the spine 650 relative to four
  • Electrodes 660 that are spaced therearound. A skin boundary or layer of the patient
  • muscle 680 is generally shown at 670 with muscle 680 being shown as occupying the area
  • Fig. 13 is also a geometric model illustrating an enlargement of the
  • the electrode 670 and the skin layer 670.
  • the axis units in Fig. 13 are in millimeters and in this exemplary embodiment, the electrode 660 includes a coating 662 that is
  • the electrode 660 has a
  • the skin layer 670 has a thickness of about 0.1mm.
  • Table 1 sets forth the parameters for the materials that are
  • electrodes 660 was IV and the frequency of the sine voltage was lOOKHz.
  • the electrodes 660 are placed in a symmetric configuration
  • Fig. 14 is
  • FIG. 15 is another representation of the electric field; however, this representation of the
  • Fig. 16 is a schematic illustration of the arrangement of the electrodes 660 that
  • Fig. 17 is a photographic image
  • Electrodes causes a zero electric field in the area of the spine 650, while the field
  • procedure can entail using a CT image to position the internal organs, calculate on-
  • the isolects 200 are the insulators of the isolects 230 (see Figs. 19-21).
  • the isolects 200 are the insulators of the isolects 230 (see Figs. 19-21).
  • the isolects 200 are the insulators of the isolects 230 (see Figs. 19-21).
  • the isolects 200 are the insulators of the isolects 230 (see Figs. 19-21).
  • apparatus 200 or one of the others disclosed herein can be used. The following
  • FIG. 19 illustrates an exemplary embodiment
  • the skin patch 700 can
  • the patch be a self-adhesive flexible patch with one or more pairs of isolects 230.
  • 700 includes internal insulation 710 (formed of a dielectric material) and the
  • external insulation 260 is applied to skin surface 701 that contains a tumor 703
  • Tissue is
  • the internal insulation 710 must have a
  • insulation 710 can be made very thin and/or the internal insulation 710 can be of a
  • present TC fields e.g., 50KHz to 500KHz.
  • present TC fields e.g., 50KHz to 500KHz.
  • impedance to be about 10K Ohms or less, such that over 1 % of the applied voltage
  • layer 710 should be about 50-100 microns. An internal field 10 times stronger
  • Figs. 20 and 21 illustrate a second type of treatment using the isolects
  • isolects 230 are implanted is generally indicated at 711 and includes a skin surface
  • the isolects 230 can have the shape of
  • Fig. 22 illustrates the various constructions of the isolects 230
  • liver, lung, etc. the distance between each member of the pair of isolects
  • the pairs can even by positioned opposite sides of a torso 720, as
  • Fig. 23 The arrangement of the isolects 230 in Fig. 23 is particularly
  • the electric fields spread in a wide fraction
  • dielectric coating of each should be very thin, for example from between 1-50
  • isolect' s structure so as to provide desired protection from such damage.
  • the isolect 230 can be coated, for example, with a relatively loose net 340
  • the loose net 340 can be formed of a number of
  • the net 340 is formed
  • exemplary conductive coating is formed of a metal and more particularly of gold.
  • the thickness of the coating 350 depends upon the particular application and also on
  • the coating 350 has a thickness from about 0.1 micron to about 0.1 mm.
  • the isolects insulating material should be any material and field parameters. The isolects insulating material.
  • the isolects 230 over the body can be maintained using any number of different
  • Fig. 25 illustrates such an arrangement in which an area
  • P represents a protected area. The lines of field force do not penetrate
  • the present inventor has thus uncovered that electric fields having particular properties can be used to destroy dividing cells or tumors when the
  • the alternating electric potential applies to the
  • tissue being treated is rotated relative to the tissue using conventional devices, such as
  • the generator 210 and the control system thereof can be any suitable generator.
  • the control system thereof can be any suitable generator.
  • TC fields have maximal effect when they are parallel to the axis of cell division.
  • dividing cells are affected by a given TC field.
  • FIG. 26 in which an article of clothing 800 according
  • clothing 800 is in the form of a hat or cap or other type of clothing designed for
  • a head 802 is shown
  • An intra-cranial tumor or the like 810 is shown as being formed within the tumor
  • the hat 800 is therefore intended
  • the insulated electrodes 230 are arranged in a more or less planar arrangement since
  • the insulated electrodes 230 in this embodiment are specifically contoured and
  • lesions or the like typically requires a treatment that is of a relatively long duration
  • the hat 800 is specifically designed to provide comfort
  • the hat 800 includes a
  • tumor 810 is positioned within these lines of force 820. As will be described in
  • the insulated electrodes 230 are positioned within the hat
  • the head 802. when the patient wears the hat 800, the insulated
  • Electrodes 230 are placed in contact with the skin surface 804 of the head 802 in
  • head 802 is shaved in selected areas to permit better contact between the insulated
  • electrodes 230 and the skin surface 804 are not critical.
  • the hat 800 preferably includes a mechanism 830 that applies or
  • the mechanism 830 can be of a biasing type that applies a
  • the insulated electrodes 230 are pressed against the skin
  • the mechanism 830 can slightly recoil to
  • the mechanism 830 is a spring based device that is disposed within the hat 800 and has one section that is coupled to and applies a force
  • the insulated electrodes 230 are
  • the generator 210 can be any generator 210 that can be coupled to the generator 210 by means of conductors 220.
  • the generator 210 can be any generator 210.
  • independent system or the generator 210 can be disposed external to the
  • the generator 210 can be located in any location.
  • the hat 800 itself, while others can be further away from the hat 800.
  • the hat 800 itself, while others can be further away from the hat 800.
  • the hat 800 can be further away from the hat 800.
  • generator 210 can be disposed within a carrying bag or the like (e.g. , a bag that
  • the generator 210 can also be
  • the protective case can be any suitable clothing that is worn by the patient.
  • the protective case can be any suitable clothing that is worn by the patient.
  • the protective case can be any suitable clothing that is worn by the patient.
  • the protective case can be any suitable clothing that is worn by the patient.
  • the protective case can be any suitable clothing that is worn by the patient.
  • the protective case can be any suitable clothing that is worn by the patient.
  • the protective case can be any suitable clothing that is worn by the patient.
  • the protective case can be any suitable clothing that is worn by the patient.
  • Fig. 26 illustrates an embodiment where the
  • generator 210 is incorporated directly into the hat 800.
  • insulated electrodes 230 along with the mechanism 830 are preferably
  • the hat 800 and electrically connected to the generator (not shown) via the
  • the patient can easily insert and/or remove the units 840 from the hat 800 when they may need cleaning, servicing and/or replacement.
  • the hat 800 is constructed to include select areas
  • each area 850 is in the form of an opening (pore) that is
  • the unit 840 has a body 842 and includes the
  • the mechanism 830 is configured to control the mechanism 830 and one or more insulated electrodes 230.
  • the mechanism 830 is
  • a portion thereof e.g. , one end thereof
  • the hat 800 can include pivotable clip
  • the insulated electrodes 230 are retained within the openings 850 by an adhesive
  • element 860 which in one embodiment is a two sided self-adhesive rim member that
  • adhesive rim 860 is removed for application to the skin surface 804 in desired locations for positioning and securing the insulated electrode 230 to the head 802
  • the tumor being positioned relative thereto for optimization of the TC fields.
  • adhesive rim 860 can be placed flushly against the skin surface 840.
  • the adhesive rim 860 is designed to securely attach the unit 840
  • the unit 840 includes the biasing
  • the unit 840 can be constructed so that side opposite the
  • insulated electrode 230 is a support surface formed of a rigid material, such as
  • biasing mechanism 830 e.g., a spring
  • biasing force at its other end against the insulated electrode 230.
  • mechanism 830 e.g., spring
  • the insulated electrode 230 to have a contour complementary to the skin surface 804,
  • mechanism 830 can be a spring, there are a number of other embodiments that can
  • the mechanism 830 can be in the form of
  • an elastic material such as a foam rubber, a foam plastic, or a layer containing air bubbles, etc.
  • the unit 840 has an electric connector 870 that can be hooked up to a
  • a corresponding electric connector such as a conductor 220, that is disposed within
  • the conductor 220 connects at one end to the unit 840 and at the other
  • the generator 210 can be incorporated
  • the generator 210 can be positioned separately (remotely)
  • a coupling agent such as a conductive gel
  • the coupling agent is disposed on the insulated electrode 230 and preferably, a uniform
  • the patient removes the units
  • Figs. 29 and 30 illustrate another article of clothing which has the
  • insulated electrodes 230 incorporated as part thereof. More specifically, a bra or
  • the like 900 is illustrated and includes a body that is formed of a traditional bra
  • the bra 900 also includes a fabric support layer 910 on one side thereof.
  • the support layer 910 is preferably formed of a suitable fabric material that is
  • bra 900 constructed to provide necessary and desired support to the bra 900.
  • the bra 900 includes one or more
  • insulated electrodes are disposed along an inner surface of the bra 900 opposite the
  • the insulated electrodes 230 in this embodiment are
  • the msulated electrodes 230 used in this application do not have a
  • planar surface construction but rather have an arcuate shape that is complementary
  • a lining 920 is disposed across the insulated electrodes 230 so as to
  • the lining 920 can be formed of any material
  • the lining 920 is formed of a fabric material.
  • the bra 900 also preferably includes a biasing mechanism 1000 as in
  • the biasing mechanism 1000 is disposed within
  • the bra material 905 and extends from the support 910 to the insulated electrode 230
  • the biasing mechanism 1000 can be in

Description

APPARATUS AND METHOD FOR OPTIMIZING TUMOR TREATMENT
EFFICIENCY BY ELECTRIC FIELDS
CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. patent application serial
No. 10/402,327, filed March 28, 2003, which is hereby incorporated by reference
in its entirety.
FIELD OF THE INVENTION
The present invention relates to the selective destruction of rapidly
dividing cells in a localized area, and more particularly, to an apparatus and method
for optimizing the selective destruction of dividing cells by calculating the spatial
and temporal distribution of electric fields for optimal treatment of a specific patient
with a specific tumor taking into account its location and characteristics.
BACKGROUND OF THE INVENTION
All living organisms proliferate by cell division, including cell
cultures, microorganisms (such as bacteria, mycoplasma, yeast, protozoa, and other
single-celled organisms), fungi, algae, plant cells, etc. Dividing cells of organisms can be destroyed, or their proliferation controlled, by methods that are based on the
sensitivity of the dividing cells of these organisms to certain agents. For example,
certain antibiotics stop the multiplication process of bacteria.
The process of eukaryotic cell division is called "mitosis", which
involves a number of distinct phases. During interphase, the cell replicates
chromosomal DNA, which begins condensing in early prophase. At this point,
centrioles (each cell contains 2) being moving towards opposite poles of the cell. In
middle prophase, each chromosome is composed of duplicate chromatids.
Microtubular spindles radiate from regions adjacent to the centrioles, which are
closer to their poles. By late prophase, the centrioles have reached the poles, and
some spindle fibers extend to the center of the cell, while others extend from the
poles to the chromatids. The cells then move into metaphase, when the
chromosomes move toward the equator of the cell and align in the equatorial plane.
Next is early anaphase, during which time daughter chromatids separate from each
other at the equator by moving along the spindle fibers toward a centromere at
opposite poles. The cell begins to elongate along the axis of the pole; the pole-to-
pole spindles elongate. Late anaphase occurs when the daughter chromosomes (as
they are now called) each reach their respective opposite poles. At this point,
cytokinesis begins as the cleavage furrow begins to form at the equator of the cell.
In other words, late anaphase is the point at which pinching the cell membrane
begins. During telophase, cytokinesis is nearly complete and spindles disappear.
Only a relatively narrow membrane connection joins the two cytoplasms. Finally,
the membranes separate fully, cytokinesis is complete and the cell returns to interphase.
In meiosis, the cell undergoes a second division, involving separation
of sister chromosomes to opposite poles of the cell along spindle fibers, followed by
formation of a cleavage furrow and cell division. However, this division is not
preceded by chromosome replication, yielding a haploid germ cell.
It is known in the art that tumors, particularly malignant or cancerous
tumors, grow very uncontrollably compared to normal tissue. Such expedited
growth enables tumors to occupy an ever-increasing space and to damage or destroy
tissue adjacent thereto. Furthermore, certain cancers are characterized by an ability
to transmit cancerous "seeds", including single cells or small cell clusters
(metastasises), to new locations where the metastatic cancer cells grow into
additional tumors.
The rapid growth of tumors in general, and malignant tumors in
particular, as described above, is the result of relatively frequent cell division or
multiplication of these cells compared to normal tissue cells. The distinguishably
frequent cell division of cancer cells is the basis for the effectiveness of existing
cancer treatments, e.g., irradiation therapy and the use of various chemo-therapeutic
agents. Such treatments are based on the fact that cells undergoing division are
more sensitive to radiation and chemo-therapeutic agents than non-dividing dells.
Because tumor cells divide much more frequently than normal cells, it is possible, to
a certain extent, to selectively damage or destroy tumor cells by radiation therapy
and/or by chemotherapy. The actual sensitivity of cells to radiation, therapeutic agents, etc., is also dependent on specific characteristics of different types of normal
or malignant cell type. Thus, unfortunately, the sensitivity of tumor cells is not
sufficiently higher than that of many types of normal tissues. This diminishes the
ability to distinguish between tumor cells and normal cells and, therefore, existing
cancer treatments typically cause significant damage to normal tissues, thus limiting
the therapeutic effectiveness of such treatments. Furthermore, the inevitable
damage to other tissue renders treatments very traumatic to the patients and, often,
patients are unable to recover from a seemingly successful treatment. Also, certain
types of tumors are not sensitive at all to existing methods of treatment.
There are also other methods for destroying cells that do not rely on
radiation therapy or chemotherapy alone. For example, ultrasonic and electrical
methods for destroying tumor cells can be used in addition to or instead of
conventional treatments. Electric fields and currents have been used for medical
purposes for many years. The most common is the generation of electric currents in
a human or animal body by application of an electric field by means of a pair of
conductive electrodes between which a potential difference is maintained. These
electric currents are used either to exert their specific effects, i.e., to stimulate
excitable tissue, or to generate heat by flowing in the body since it acts as a resistor.
Examples of the first type of application include the following: cardiac
defibrillators, peripheral nerve and muscle stimulators, brain stimulators, etc.
Currents are used for heating, for example, in devices for tumor ablation, ablation
of malfunctioning cardiac or brain tissue, cauterization, relaxation of muscle
rheumatic pain and other pain, etc. Another use of electric fields for medical purposes involves the
utilization of high frequency oscillating fields transmitted from a source that emits
an electric wave, such as an RF wave or a microwave source that is directed at the
part of the body that is of interest (i.e. , target). In these instances, there is no
electric energy conduction between the source and the body; but rather, the energy
is transmitted to the body by radiation or induction. More specifically, the electric
energy generated by the source reaches the vicinity of the body via a conductor and
is transmitted from it through air or some other electric insulating material to the
human body.
In a conventional electrical method, electrical current is delivered to a
region of the target tissue using electrodes that are placed in contact with the body
of the patient. The applied electrical current destroys substantially all cells in the
vicinity of the target tissue. Thus, this type of electrical method does not
discriminate between different types of cells within the target tissue and results in
the destruction of both tumor cells and normal cells.
Electric fields that can be used in medical applications can thus be
separated generally into two different modes. In the first mode, the electric fields
are applied to the body or tissues by means of conducting electrodes. These electric
fields can be separated into two types, namely (1) steady fields or fields that change
at relatively slow rates, and alternating fields of low frequencies that induce
corresponding electric currents in the body or tissues, and (2) high frequency
alternating fields (above 1MHz) applied to the body by means of the conducting electrodes. In the second mode, the electric fields are high frequency alternating
fields applied to the body by means of insulated electrodes.
The first type of electric field is used, for example, to stimulate
nerves and muscles, pace the heart, etc. In fact, such fields are used in nature to
propagate signals in nerve and muscle fibers, central nervous system (CNS), heart,
etc. The recording of such natural fields is the basis for the ECG, EEG, EMG,
ERG, etc. The field strength in these applications, assuming a medium of
homogenous electric properties, is simply the voltage applied to the
stimulating/recording electrodes divided by the distance between them. These
currents can be calculated by Ohm's law and can have dangerous stimulatory effects
on the heart and CNS and can result in potentially harmful ion concentration
changes. Also, if the currents are strong enough, they can cause excessive heating
in the tissues. This heating can be calculated by the power dissipated in the tissue
(the product of the voltage and the current).
When such electric fields and currents are alternating, their
stimulatory power, on nerve, muscle, etc., is an inverse function of the frequency.
At frequencies above 1-10 KHz, the stimulation power of the fields approaches
zero. This limitation is due to the fact that excitation induced by electric stimulation
is normally mediated by membrane potential changes, the rate of which is limited by
the RC properties (time constants on the order of 1 ms) of the membrane.
Regardless of the frequency, when such current inducing fields are
applied, they are associated with harmful side effects caused by currents. For example, one negative effect is the changes in ionic concentration in the various
"compartments" within the system, and the harmful products of the electrolysis
taking place at the electrodes, or the medium in which the tissues are imbedded.
The changes in ion concentrations occur whenever the system includes two or more
compartments between which the organism maintains ion concentration differences.
For example, for most tissues, [Ca++] in the extracellular fluid is about 2 x 10"3 M,
while in the cytoplasm of typical cells its concentration can be as low as 10"7 M. A
current induced in such a system by a pair of electrodes, flows in part from the
extracellular fluid into the cells and out again into the extracellular medium. About
2% of the current flowing into the cells is carried by the Ca++ ions. In contrast,
because the concentration of intracellular Ca++ is much smaller, only a negligible
fraction of the currents that exits the cells is carried by these ions. Thus, Ca++ ions
accumulate in the cells such that their concentrations in the cells increases, while the
concentration in the extracellular compartment may decrease. These effects are
observed for both DC and alternating currents (AC). The rate of accumulation of
the ions depends on the current intensity ion mobilities, membrane ion conductance,
etc. An increase in [Ca++] is harmful to most cells and if sufficiently high will lead
to the destruction of the cells. Similar considerations apply to other ions. In view
of the above observations, long term current application to living organisms or
tissues can result in significant damage. Another major problem that is associated
with such electric fields, is due to the electrolysis process that takes place at the
electrode surfaces. Here charges are transferred between the metal (electrons) and
the electrolytic solution (ions) such that charged active radicals are formed. These can cause significant damage to organic molecules, especially macromolecules and
thus damage the living cells and tissues.
In contrast, when high frequency electric fields, above 1 MHz and
usually in practice in the range of GHz, are induced in tissues by means of insulated
electrodes, the situation is quite different. These type of fields generate only
capacitive or displacement currents, rather than the conventional charge conducting
currents. Under the effect of this type of field, living tissues behave mostly
according to their dielectric properties rather than their electric conductive
properties. Therefore, the dominant field effect is that due to dielectric losses and
heating. Thus, it is widely accepted that in practice, the meaningful effects of such
fields on living organisms, are only those due to their heating effects, i.e., due to
dielectric losses.
In U.S. Patent No. 6,043,066 ('066) to Mangano, a method and
device are presented which enable discrete objects having a conducting inner core,
surrounded by a dielectric membrane to be selectively inactivated by electric fields
via irreversible breakdown of their dielectric membrane. One potential application
for this is in the selection and purging of certain biological cells in a suspension.
According to this patent, an electric field is applied for targeting selected cells to
cause breakdown of the dielectric membranes of these tumor cells, while
purportedly not adversely affecting other desired subpopulations of cells. The cells are selected on the basis of intrinsic or induced differences in a characteristic
electroporation threshold. The differences in this threshold can depend upon a number of parameters, including the difference in cell size.
The method of the '066 patent is therefore based on the assumption
that the electroporation threshold of tumor cells is sufficiently distinguishable from
that of normal cells because of differences in cell size and differences in the
dielectric properties of the cell membranes. Based upon this assumption, the larger
size of many types of tumor cells makes these cells more susceptible to
electroporation and thus, it may be possible to selectively damage only the larger
tumor cell membranes by applying an appropriate electric field. One disadvantage
of this method is that the ability to discriminate is highly dependent upon on cell
type, for example, the size difference between normal cells and tumor cells is
significant only in certain types of cells. Another drawback of this method is that
the voltages which are applied may damage some of the normal cells and may not \
damage all of the tumor cells because the differences in size and membrane
dielectric properties are largely statistical and the actual cell geometries and
dielectric properties may vary significantly.
What is needed in the art and has heretofore not been available is an
apparatus for destroying dividing cells, wherein the apparatus better discriminates
between dividing cells, including single-celled organisms, and non-dividing cells
and is capable of selectively destroying the dividing cells or organisms with
substantially no affect on the non-dividing cells or organisms and which can be
configured to adopt its characteristics and spatial distribution within the patient's
body so as to optimally destroy a specific tumor or tumors in a patient. The data regarding the specific tumor can be provided by conventional techniques, such as
CT, MRI, etc. , imaging of the tumor and its' surroundings, as well as other means
for characterization of the tumors.
SUMMARY OF THE INVENTION An apparatus and related method for use in a number of different
applications for optimization of the selective electric fields in destroying cells
undergoing growth and division are provided. This includes cell (particularly tumor
cells) in living tissues and organisms or other complex structures. The apparatus
and method are designed to compute the optimal spatial and temporal characteristics
for combating tumor growth within a body on the basis of cytological (as provided
by biopsies, etc.) and anatomical data (as provided by CT, MRI, PET, etc.), as well
as the electric properties of the different elements. On the basis of this computation,
the apparatus applies the fields that have maximal effect on the tumor and minimal
effect on all other tissues by adjusting both the field generator output characteristics
and by optimal positioning of the insulated electrodes or isolects on the patient's
body. For example and as will be described in greater detail hereinafter, the
isolects are directly applied to the patient or by means of probes or pieces of
clothing that are worn over the tumor area. In either case, the apparatus can
activate the selected set of electrodes (isolects) to achieve optimal effect.
A major use of the method and apparatus of the present invention is
in treatment of tumors by selective destruction of tumor cells with substantially no
affect on normal tissue cells and, thus, the invention is described below in the context of selective destruction of tumor cells. It should be appreciated however
that, for the purpose of the description that follows, the term "cell" may also refer to
single-celled organisms (eubacteria, bacteria, yeast, protozoa), multi-celled
organisms (fungi, algae, mold), and plants as or parts thereof that are not normally
classified as "cells". The method of the present invention enables selective
destruction of tumor cells, or other organisms, by selective destruction of cells
undergoing division in a way that is more effective and more accurate (e.g., more
adaptable to be aimed at specific targets) than existing methods. Further, the
method of the present invention causes minimal damage, if any, to normal tissue
and, thus, reduces or eliminates many side-effects associated with existing selective
destruction methods, such as radiation therapy and chemotherapy. The selective
destruction of dividing cells in accordance with the method of the present invention
does not depend on the sensitivity of the cells to chemical agents or radiation.
Instead, the selective destruction of dividing cells is based on distinguishable
geometrical characteristics of cells undergoing division, in comparison to non-
dividing cells, regardless of the cell geometry of the type of cells being treated. As
well as the electric properties of the special apparatus associated with cell division
(microtubules, tubulin filaments, etc.).
In an embodiment of the present invention, cell geometry-dependent
selective destruction of living tissue is performed by inducing a non-homogenous electric field in the cells, as described below.
It has been observed by the present inventor that, while different cells in their non-dividing state may have different shapes, e.g., spherical, ellipsoidal,
cylindrical, "pancake-like", etc., the division process of practically all cells is
characterized by development of a "cleavage furrow" in late anaphase and
telophase. This cleavage furrow is a slow constriction of the cell membrane
(between the two sets of daughter chromosomes) which appears microscopically as a
growing cleft (e.g., a groove or notch) that gradually separates the cell info two new
cells. During the division process, there is a transient period (telophase) during
which the cell structure is basically that of two sub-cells interconnected by a narrow
"bridge" formed of the cell material. The division process is completed when the
"bridge" between the two sub-cells is broken. The selective destruction of tumor
cells using the present electronic apparatus utilizes this unique geometrical feature of
dividing cells.
When a cell or a group of cells are under natural conditions or
environment, i.e., part of a living tissue, they are disposed surrounded by a
conductive environment consisting mostly of an electrolytic inter-cellular fluid and
other cells that are composed mostly of an electrolytic intra-cellular liquid. When
an electric field is induced in the living tissue, by applying an electric potential
across the tissue, an electric field is formed in the tissue and the specific distribution
and configuration of the electric field lines defines the direction of charge
displacement, or paths of electric currents in the tissue, if currents are in fact induced in the tissue. The distribution and configuration of the electric field is
dependent on various parameters of the tissue, including the geometry and the
electric properties of the different tissue components, and the relative conductivities, capacities and dielectric constants (that may be frequency dependent) of the tissue
components.
The electric current flow pattern for cells undergoing division is very
different and unique as compared to non-dividing cells. Such cells including first
and second sub-cells, namely an "original" cell and a newly formed cell, that are
connected by a cytoplasm "bridge" or "neck" . The currents penetrate the first sub-
cell through part of the membrane ("the current source pole"); however, they do not
exit the first sub-cell through a portion of its membrane closer to the opposite pole
("the current sink pole"). Instead, the lines of current flow converge at the neck or
cytoplasm bridge, whereby the density of the current flow lines is greatly increased.
A corresponding, "mirror image", process that takes place in the second sub-cell,
whereby the current flow lines diverge to a lower density configuration as they
depart from the bridge, and finally exit the second sub-cell from a part of its
membrane closes to the current sink.
When a polarizable object is placed in a non-uniform converging or
diverging field, electric forces act on it and pull it towards the higher density
electric field lines. In the case of dividing cell, electric forces are exerted in the
direction of the cytoplasm bridge between the two cells. Since all intercellular
organelles and macromolecules are polarizable, they are all force towards the bridge
between the two cells. The field polarity is irrelevant to the direction of the force
and, therefore, an alternating electric having specific properties can be used to
produce substantially the same effect. It will also be appreciated that the concentrated and inhomogeneous electric field present in or near the bridge or neck
portion in itself exerts strong forces on charges and natural dipoles and can lead to
the disruption of structures associated with these members.
The movement of the cellular organelles towards the bridge disrupts
the cell structure and results in increased pressure in the vicinity of the connecting
bridge membrane. This pressure of the organelles on the bridge membrane is
expected to break the bridge membrane and, thus, it is expected that the dividing
cell will "explode" in response to this pressure. The ability to break the membrane
and disrupt other cell structures can be enhanced by applying a pulsating alternating
electric field that has a frequency from about 50KHz to about 500KHz. When this
type of electric field is applied to the tissue, the forces exerted on the intercellular
organelles have a "hammering" effect, whereby force pulses (or beats) are applied
to the organelles numerous times per second, enhancing the movement of organelles
of different sizes and masses towards the bridge (or neck) portion from both of the
sub-cells, thereby increasing the probability of breaking the cell membrane at the
bridge portion. The forces exerted on the intracellular organelles also affect the
organelles themselves and may collapse or break the organelles.
According to one exemplary embodiment, the apparatus for applying
the electric field is an electronic apparatus that generates the desired electric signals
in the shape of waveforms or trains of pulses. The electronic apparatus includes a generator that generates an alternating voltage waveform at frequencies in the range
from about 50KHz to about 500KHz. The generator is operatively connected to conductive leads which are connected at their other ends to insulated
conductors/electrodes (also referred to as isolects) that are activated by the
generated waveforms. The generator may provide each electrode with a specific
selected waveform that is calculated for field distribution that gives optimal results.
This can be represented in the form of an Optimal Map. The insulated electrodes
consist of a conductor in contact with a dielectric (insulating layer) that is in contact
with the conductive tissue, thus forming a capacitor. The electric fields that are
generated by the present apparatus can be applied in several different modes
depending upon the precise treatment application and physiological and anatomical
characteristics of the patient's parts of the body undergoing treatment.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1A-1E are simplified, schematic, cross-sectional, illustrations of
various stages of a cell division process;
Figs. 2A and 2B are schematic illustrations of a non-dividing cell
being subjected to an electric field, in accordance with an embodiment of the present
invention;
Figs. 3 A, 3B and 3C are schematic illustrations of a dividing cell
being subjected to an electric field, resulting in destruction of the cell (Fig. 3C), in accordance with an embodiment of the present invention;
Fig 4 is a schematic illustration of a dividing cell at one stage being
subjected to an electric field;
Fig. 5 is a schematic block diagram of an apparatus for applying an electric field according to one exemplary embodiment for selectively destroying
cells;
Fig. 6 is a simplified schematic diagram of an equivalent electric
circuit of insulated electrodes of the apparatus of Fig. 5;
Fig. 7 is diagrammatic flow chart for computing an optimal electric
field;
Fig. 8 is a front elevation view of an undershirt incorporating the
present apparatus being worn over a human body;
Fig. 9 is a cross-sectional taken along the line 9-9;
Fig. 10 is schematic view of a target area on which the electric field
is to be focused;
Fig. 11 is a photographic image of the optimal position of electrodes
around the target area (tissue mass) of Fig. 10;
Fig. 12 is a schematic illustration of a geometric model for
positioning electrodes around a spine of a human patient where the electrodes are
arranged symmetrically;
Fig. 13 is an enlarged schematic illustration of one electrode of the
arrangement of Fig. 12;
Fig. 14 is a photographic image of a resulting electric field generated
when the electrodes are arranged symmetrically as illustrated in Fig. 12;
Fig. 15 is a schematic illustration representing the electric field of Fig. 14 by arrows;
Fig. 16 is a schematic illustration of a geometric model for
positioning electrodes around the spine in an asymmetric manner so that the electric
field in the area of the spine is zero;
Fig. 17 is a photographic image of a resulting electric field generated
when the electrodes are arranged asymmetrically as illustrated in Fig. 16;
Fig. 18 is a schematic illustration representing the electric field of
Fig. 17 by arrows;
Fig. 19 is a cross-sectional illustration of a skin patch incorporating
the apparatus of Fig. 5 and for placement on a skin surface for treating a tumor or
the like;
Fig. 20 is a cross-sectional illustration of the insulated electrodes
implanted within the body for treating a tumor or the like;
Fig. 21 is a cross-sectional illustration of the insulated electrodes
implanted within the body for treating a tumor or the like;
Figs. 22A-22D are cross-sectional illustrations of various
constructions of the insulated electrodes of Fig. 5;
Fig. 23 is a front elevation view in partial cross-section of two
insulated electrodes being arranged about a human torso for treatment of a tumor
contained within the body, e.g., a tumor associated with lung cancer;
Figs. 24A-24C are cross-sectional illustrations of various insulated electrodes with and without protective members formed as a part of the construction
thereof;
Fig. 25 is a schematic diagram of insulated electrodes that are
arranged for focusing the electric field at a desired target while leaving other areas
in low field density (i.e., protected areas);
Fig. 26 is a cross-sectional view of insulated electrodes incorporated
into a hat according to a first embodiment for placement on a head for treating an
intra-cranial tumor or the like;
Fig. 27 is a partial section of a hat according to an exemplary
embodiment having a recessed section for receiving one or more insulated
electrodes;
Fig. 28 is a cross-sectional view of the hat of Fig. 27 placed on a
head and illustrating a biasing mechanism for applying a force to the insulated
electrode to ensure the insulated electrode remains in contact against the head;
Fig. 29 is a cross-sectional top view of an article of clothing having
the insulated electrodes incorporated therein for treating a tumor or the like;
Fig. 30 is a cross-sectional view of a section of the article of clothing
of Fig. 29 illustrating a biasing mechanism for biasing the insulated electrode in a
direction to ensure the insulated electrode is placed proximate to a skin surface where treatment is desired;
Fig. 31 is a cross-sectional view of a probe according to one embodiment for being disposed internally within the body for treating a tumor or the
like;
Fig. 32 is an elevation view of an unwrapped collar according to one
exemplary embodiment for placement around a neck for treating a tumor or the like
in the area where the collar is wrapped around the neck;
Fig. 33 is a side elevation view of the present apparatus being used to
prevent restenosis of arteries after angioplasty; and
Fig. 34 is an enlarged view of a stent used in the arrangement of Fig.
33.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS THE
INVENTION
Reference is made to Figs. 1A-1E which schematically illustrate
various stages of a cell division process. Fig. 1A shows a cell 10 at its normal
geometry, which may be generally spherical (as shown in the drawings), ellipsoidal,
cylindrical, "pancake" like, or any other cell geometry, as is known in the art. Figs.
IB-ID show cell 10 during different stages of its division process, which results in
the formation of two new cells 18 and 20, shown in Fig. IE.
As shown in Figs. IB-ID, the division process of cell 10 is
characterized by a slowly growing cleft 12 which gradually separates cell 10 into
two units, namely, sub-cells 14 and 16, which eventually evolve into new cells 18
and 20 (Fig. IE). As shown specifically in Fig. ID, the division process is
characterized by a transient period during which the structure of cell 10 is basically that of the two sub-cells 14 and 16 interconnected by a narrow "bridge" 22
containing cell material (cytoplasm surrounded by cell membrane).
Reference is now made to Figs. 2A and 2B, which schematically
illustrate non-dividing cell 10 being subjected to an electric field produced by
applying an alternating electric potential, at a relatively low frequency and at a
relatively high frequency, respectively. Cell 10 includes intracellular organelles,
e.g. , a nucleus 30. Alternating electrical potential is applied across electrodes 28
and 32 that may be attached externally to a patient at a predetermined region, e.g.,
in the vicinity of a tumor being treated. When cell 10 is under natural conditions,
i.e., part of a living tissue, it is disposed in a conductive environment (hereinafter
referred to as a "volume conductor") consisting mostly of electrolytic inter-cellular
liquid. When an electric potential is applied across electrode 28 and 32, some of the
field lines of the resultant electric field (or the current induced in the tissue in
response to the electric field) penetrate cell 10, while the rest of the field lines (or
induced current) flow in the surrounding medium. The specific distribution of the
electric field lines, which is substantially consistent with the direction of current
flow in this case, depends on the geometry and the electric properties of the system
components, e.g., the relative conductivities and dielectric constants of the system
components, that may be frequency dependent. For low frequencies, e.g.,
frequencies considerably lower than 10 kHz, the conductance properties of the components dominate the current flow, and the field distribution is generally as
depicted in Fig. 2A. At higher frequencies, e.g., at frequencies of between 10 kHz
and 1 MHz, the dielectric properties of the components become more significant and eventually dominate the field distribution, resulting in field distribution lines as
depicted generally in Fig. 2B.
For constant (i.e., DC) electric fields or relatively low frequency
alternating electric fields, for example, frequencies under 10 kHz, the dielectric
properties of the various components are not significant in determining and
computing the field distribution. Therefore, as a first approximation, with regard to
the electric field distribution, the system can be reasonably represented by the
relative impedances of its various components. Under this approximation, the
intercellular (i.e., extracellular) fluid and the intracellular fluid have a relatively low
impedance, while the cell membrane 11 has a relatively high impedance. Thus,
under low frequency conditions, only a fraction of the electric field lines (or
currents induced by the electric field) penetrate membrane 11 of cell 10. At
relatively high frequencies (e.g., 10 kHz - 1 MHz), in contrast, the impedance of
membrane 11 relative to the intercellular and intracellular fluids decreases and, thus,
the fraction of currents penetrating the cells increases significantly. It should be
noted that at very high frequencies, i.e., above 1 MHz, the membrane capacitance
may short the membrane resistance and, therefore, the total membrane resistance
may become negligible.
In any of the embodiments described above, the electric field lines (or
induced currents) penetrate cell 10 from a portion of membrane 11 closest to one of
the electrodes generating the current, e.g., closest to positive electrode 28 (also
referred to herein as "source"). The current flow pattern across cell 10 is generally uniform because, under the above approximation, the field induced inside the cell is
substantially homogenous. The currents exit cell 10 through a portion of membrane
11 closest to the opposite electrode, e.g., negative electrode 32 (also referred to
herein as "sink").
The distinction between field lines and current flow may depend on a
number of factors, for example, on the frequency of the applied electric potential
and on whether electrodes 28 and 32 are electrically insulated. For insulated
electrodes applying a DC or low frequency alternating voltage, there is practically
no current flow along the lines of the electric field. At higher frequencies,
displacement currents are induced in the tissue due to charging and discharging of
the cell membranes (which act as capacitors to a certain extent), and such currents
follow the lines of the electric field. Fields generated by non-insulated electrodes,
in contrast, always generate some form of current flow, specifically, DC or low
frequency alternating fields generate conductive current flow along the field lines,
and high frequency alternating fields generate both conduction and displacement
c rrents along the field lines. It should be appreciated, however, that movement of
polarizable intracellular organelles according to the present invention (as described
below) is not dependent on actual flow of current and, therefore, both insulated and
non-insulated electrodes may be used efficiently in conjunction with the present
invention. Nevertheless, insulated electrodes have the advantage of lower power consumption and causing less heating of the treated regions.
According to one exemplary embodiment, the electric fields that are used in the present apparatus are alternating fields having frequencies that in the
range from about 50KHz to about 500KHz, and preferably from about lOOKHz to
about 300KHz. For ease of discussion, these type of electric fields are also referred
to hereinafter as "TC fields", which is an abbreviation of "Tumor Curing electric
fields", since these electric fields fall into an intermediate category (between high
and low frequency ranges) that have bio-effective field properties, while having no
meaningful stimulatory and thermal effects. These frequencies are sufficiently low
so that the system behavior is determined by the system's "Ohmic" (conductive)
properties but sufficiently high enough not to have any stimulation effect on
excitable tissues. Such a system consists of two types of elements, namely, the
intercellular, or extracellular fluid, or medium and the individual cells. The
intercellular fluid is mostly an electrolyte with a specific resistance of about 40-100
ohm*cm. As mentioned above, the cells are characterized by three elements,
namely (1) a thin, highly electric resistive membrane that coats the cell; (2) internal
cytoplasm that is mostly an electrolyte that contains numerous macromolecules and
micro-organelles, including the nucleus; and (3) membranes, similar in their electric
properties to the cell membranes, cover the micro-organelles.
When this type of system is subjected to the present TC fields (e.g.,
alternating electric fields in the frequency range of 100KHz-300KHz), most of the
lines of the electric field and currents tend away from the cells because of the high
resistive cell membrane and therefore, the lines remain in the extracellular
conductive medium. In the above recited frequency range, the actual fraction of
electric field or currents that penetrate the cells is a strong function of the frequency.
Fig. 2 schematically depicts the resulting field distribution in the
system. As illustrated, the lines of force, which also depict the lines of potential
current flow across the cell volume mostly in parallel with the undistorted lines of
force (the main direction of the electric field). In other words, the field inside the
cells is mostly homogeneous. In practice, the fraction of the field or current that
penetrates the cells is determined by the cell membrane impedance value relative to
that of the extracellular fluid. Since the equivalent electric circuit of the cell
membrane is that of a resistor and capacitor in parallel, the impedance is function of
the frequency. The higher the frequency, the lower the impedance, the larger the
fraction of penetrating current and the smaller the field distortion.
As previously mentioned, when cells are subjected to relatively weak
electric fields and currents that alternate at high frequencies, such as the present TC
fields having a frequency in the range of 50KHz to 500KHz, they have no effect on
the non-dividing cells. While the present TC fields have no detectable effect on
such systems, the situation becomes different in the presence of dividing cells.
Reference is now made to Figs. 3A-3C which schematically illustrate
the electric current flow pattern in cell 10 during its division process, under the
influence of high frequency alternating electric field in accordance with an
embodiment of the invention. The field lines or induced currents penetrate cell 10
through a part of the membrane of sub-cell 16 closer to electrode 28. However,
they do not exit through the cytoplasm bridge 22 that connects sub-cell 16 with the newly formed yet still attached sub-cell 14, or through a part of the membrane in the
vicinity of bridge 22. Instead, the electric field or current flow lines - that are
relatively widely separated in sub-cell 16 - converge as they approach bridge 22
(also referred to as "neck" 22) and, thus, the current/field line density within neck
22 is increased dramatically. A "mirror image" process takes place in sub-cell 14,
whereby the converging field lines in bridge 22 diverge as they approach the exit
region of sub-cell 14.
It should be appreciated by persons skilled in the art that homogenous
electric fields do not exert a force on electrically neutral objects, i.e., objects having
substantially zero net charge, although such objects may become polarized.
However, under a non-uniform, converging electric field, as shown in Figs. 3A-3C,
electric forces are exerted on polarized objects, moving them in the direction of the
higher density electric field lines. It will be appreciated that the concentrated
electric field that is present in the neck or bridge area in itself exerts strong forces
on charges and natural dipoles and can disrupt structures that are associated
therewith. One will understand that similar net forces act on charges in an
alternating field, again in the direction of the field of higher intensity.
In the configuration of Figs. 3 A and 3B, the direction of movement
of polarized objects is towards the higher density electric filed lines, i.e., towards
the cytoplasm bridge 22 between sub-cells 14 and 16. It is known in the art that all
intracellular organelles, for example, nuclei 24 and 26 of sub-cells 14 and 16,
respectively, are polarizable and, thus, such intracellular organelles will be electrically forced in the direction of bridge 22. Since the movement is always from
the lower density currents to the higher density currents, regardless of the field
polarity, the forces applied by the alternating electric field to organelles such as
nuclei 24 and 26 are always in the direction of bridge 22. A comprehensive
description of such forces and the resulting movement of macromolecules or
intracellular organelles, a phenomenon referred to as dielectrophoresis, is described
extensively in the literature, for example, in CL. Asbury & G. van den Engh,
Biophys. J. 74,1024-1030, 1998, the disclosure of which is incorporated herein by
reference.
The movement of organelles 24 and 26 towards bridge 22 disrupts the
structure of the dividing cell and, eventually, the pressure of the converging
organelles on bridge membrane 22 results in breakage of cell membrane 11 at the
vicinity of bridge 22, as shown schematically in Fig. 3C. The ability to break
membrane 11 at bridge 22 and to otherwise disrupt the cell structure and
organization may be enhanced by applying a pulsating AC electric field, rather than
a steady AC field. When a pulsating field is applied, the forces acting on organelles
24 and 26 may have a "hammering" effect, whereby pulsed forces beat on the
intracellular organelles at a desired rhythm, e.g., a pre-selected number of times per
second. Such "hammering" is expected to enhance the movement of intracellular
organelles towards neck 22 from both sub cells 14 and 16), thereby increasing the probability of breaking cell membrane 11 in the vicinity of neck 22.
A very important element, which is very susceptible to the special fields that develop within the dividing cells is the microtubule spindle that plays a
major role in the division process. In Fig. 4, a dividing cell 10 is illustrated, at an
earlier stage as compared to Figs. 3 A and 3B, under the influence of external TC
fields (e.g., alternating fields in the frequency range of about lOOKHz to about
300KHz), generally indicated as lines 100, with a corresponding spindle mechanism
generally indicated at 120. The lines 120 are microtubules that are known to have a
very strong dipole moment. This strong polarization makes the tubules susceptible
to electric fields. Their positive charges are located at two centrioles while two sets
of negative poles are at the center of the dividing cells and the other pair is at the
points of attachment of the microtubules to the cell membrane, generally indicated at
130. This structure forms sets of double dipoles and therefore, they are susceptible
to fields of different directions. It will be understood that the effects of the TC
fields on the dipoles does not depend on the formation of the bridge (neck) and thus,
the dipoles are influenced by the TC fields prior to the formation of the bridge
(neck).
Since the present apparatus, as described in greater detail hereinafter,
utilizes insulated electrodes, the above-mentioned negative effects obtained when
conductive electrodes are used, i.e. , ion concentration changes in the cells and the
formation of harmful agents by electrolysis, do not occur when the present
apparatus is used. This is because, in general, no actual transfer of charges takes
place between the electrodes and the medium and there is no charge flow in the
medium where the currents are capacitive, i.e., are expressed only as rotation of charges, etc. Turning now to Fig. 5, the TC fields described above that have been
found to advantageously destroy tumor cells are generated by an electronic
apparatus 200. Fig. 5 is a simple schematic diagram of the electronic apparatus 200
illustrating the major components thereof. The electronic apparatus 200 generates
the desired electric field signals (TC signals) in the shape of waveforms or trains of
pulses. The apparatus 200 includes a generator 210 and a set of pairs of conductive
leads 220 that are attached at one end thereof to the generator 210. The opposite
ends of the leads 220 are connected to the insulated conductors 230 that are
activated by the electric signals (e.g., waveforms). The insulated conductors 230
are also referred to hereinafter as "isolects" 230. Optionally and according to one exemplary embodiment, the apparatus 200 includes a temperature sensor 240 or
sensors and a control box 250 which are added to control the amplitude of the
electric field generated so not to generate excessive heating in the area that is
treated.
The generator 210 generates multiple alternating voltage waveforms
at frequencies in the range from about 50KHz to about 500KHz (preferably from
about lOOKHz to about 300KHz)(i.e., the TC fields) as instructed by a controller
300. Preferably, the controller 300 is a programmable unit, such as a personal
computer or the like, that permits the user to input certain parameters and the
controller 300 will then make the necessary computations. The controller 300 also
distributes to each electrode 230 the designated potential wave. The required
voltages are such the electric field intensity in the tissue to be treated is in the range
of about O. lV/cm, according to one exemplary embodiment, to about lOV/cm while in the other areas it is significantly lower.
When the control box 250 is included, it controls the outputs of the
generator 210 so that they will remain constant at the values preset by the user or
the control box 250. The controller 300 issues a warning or the like when the
temperature (sensed by temperature sensor 240) exceeds a preset limit.
The details of the construction of the isolects 230 is based on their
electric behavior that can be understood from their simplified electric circuit when
in contact with tissue as generally illustrated in Fig. 6. In the illustrated
arrangement, the potential drop or the electric field distribution between the
different components is determined by their relative electric impedance, i.e. , the
fraction of the field on each component is given by the value of its impedance
divided by the total circuit impedance. For example, the potential drop on element
Δ VA = A/(A+B+C+D+E). Thus, for DC or low frequency AC, practically all
the potential drop is on the capacitor (that acts as an insulator). For relatively very
high frequencies, the capacitor practically is a short and therefore, practically all the
field is distributed in the tissues. At the frequencies of the present TC fields (e.g. ,
50KHz to 500KHz), which are intermediate frequencies, the impedance of the
capacitance of the capacitors is dominant and determines the field distribution.
Therefore, in order to increase the effective voltage drop across the tissues (field
intensity), the impedance of the capacitors is to be decreased (i.e., increase their
capacitance). This can be achieved by increasing the effective area of the "plates"
of the capacitor, decrease the thickness of the dielectric or use a dielectric with high dielectric constant.
In order to optimize the field distribution, the isolects 230 are
configured differently depending upon the application in which the isolects 230 are
to be used. There are two principle modes for applying the present electric fields
(TC fields). First, the TC fields can be applied by external isolects and second, the
TC fields can be applied by internal isolects.
Since the thin insulating layer can be very vulnerable, etc. , the
insulation can be replaced by very high dielectric constant insulating materials, such
as titanium dioxide (e.g. , rutil), the dielectric constant can reach values of about
200. There a number of different materials that are suitable for use in the intended
application and have high dielectric constants. For example, some materials
include: lithium nibate (LiNbO3), which is a ferroelectric crystal and has a number
of applications in optical, pyroelectric and piezoelectric devices; yittrium iron garnet
(YIG) is a ferrimagnetic crystal and magneto-optical devices, e.g., optical isolator
can be realized from this material; barium titanate (BaTiO3) is a ferromagnetic
crystal with a large electro-optic effect; potassium tantalate (KTaO3) which is a
dielectric crystal (ferroelectric at low temperature) and has very low microwave loss
and tunability of dielectric constant at low temperature; and lithium tantalate
(LiTaθ3) which is a ferroelectric crystal with similar properties as lithium niobate
and has utility in electro-optical, pyroelectric and piezoelectric devices. It will be
understood that the aforementioned exemplary materials can be used in combination
with the present device where it is desired to use a material having a high dielectric constant.
One must also consider another factor that effects the effective
capacity of the isolects 230, namely the presence of air between the isolects 230 and
the skin. Such presence, which is not easy to prevent, introduces a layer of an
insulator with a dielectric constant of 1.0, a factor that significantly lowers the
effective capacity of the isolects 230 and neutralizes the advantages of the titanium
dioxide (routil), etc. To overcome this problem, the isolects 230 can be shaped so
as to conform with the body structure and/or (2) an intervening filler 270 (as
illustrated in Fig. 22C), such as a gel, that has high conductance and a high effective
dielectric constant, can be added to the structure. The shaping can be pre-structured
(see Fig. 22 A) or the system can be made sufficiently flexible so that shaping of the
isolects 230 is readily achievable. The gel can be made of hydrogels, gelatins, agar,
etc., and can have salts dissolved in it to increase its conductivity. The exact
thickness of the gel is not important so long as it is of sufficient thickness that the
gel layer does not dry out during the treatment. In one exemplary embodiment, the
thickness of the gel is about 0.5 mm to about 2 mm.
In order to avoid overheating of the treated tissues, a selection of
materials and field parameters is needed. The isolects insulating material should
have minimal dielectric losses at the frequency ranges to be used during the
treatment process. This factor can be taken into consideration when choosing the
particular frequencies for the treatment. The direct heating of the tissues will most
likely be dominated by the heating due to current flow (given by the I*R product). However, dielectric losses can also contribute and in addition, the isolect (insulated
electrode) 230 and its surroundings should be made of materials that facilitate heat
losses and its general structure should also facilitate head losses, i.e., minimal
structures that block heat dissipation to the surroundings (air) as well as high heat
conductivity.
As previously mentioned, a coupling agent, such as a conductive gel,
is preferably used to ensure that an effective conductive environment is provided
between the insulated electrode 230 and the skin surface 231. The coupling agent is
disposed on the insulated electrode 230 and preferably, a uniform layer of the agent
is provided along the surface of the electrode 230. One of the reasons that the units
540 need replacement at periodic times is that the coupling agent needs to be
replaced and/or replenished. In other words, after a predetermined time period or
after a number of uses, the patient removes the units 540 so that the coupling agent
can be applied again to the electrode 230.
The leads 220 are standard isolated conductors with a flexible metal
shield, preferably grounded so that it prevents the spread of the electric field
generated by the leads 220. The isolects 230 have specific shapes and positioning so
as to generate an electric field of the desired configuration, direction and intensity at
the target volume and only there so as to focus the treatment. The generation of
electric field distribution of the desired characteristics is achieved by placement of
numerous isolects on the body surface, and when necessary also inside the body.
The number of electrodes 230 can typically be about 20-100, placed about 4-12 cm apart. The electrodes 230 can be positioned individually on the skin, etc. , (as by an
adhesive), or be part of an article of clothing, such as elastic undershirt, as
illustrated in Figs. 8-9, that holds the electrodes in place. Each isolect 230
(electrode) is connected to the controller 300 and is provided with a voltage signal
the amplitude and shape of which was calculated specifically for the particular
electrode. One will also appreciate that the calculation for the voltage signal
(amplitude and shape) can be made for groups of isolects as well instead of for
individual isolects.
According to one aspect, a method for optimizing the selective
destruction of dividing cells is provided and the method includes the general steps of
calculating the spatial and temporal distribution of electric fields for optimal
treatment of a specific patient that has a tumor of specific characteristics. This
calculation takes into consideration the location and the specific characteristics of
the tumor.
One exemplary process for computing and applying an optimal
electric field is described with reference to the flow chart of Fig. 7. Fig. 7 thus
gives a general overview of the present optimization process. In steps 400, 410,
420, the user inputs different types of information that is used to compute the
optimal electric field. For example, at step 400, the user inputs characteristics of
the tissue cells in the area to be treated; at step 410, the user inputs characteristics of the tumor cells to be treated; and at step 420, the user inputs the anatomy of the area
to be treated, including the tumor and its relevant surroundings. At step 430, this inputted information is used to compute the necessary field intensity in the tumor.
The relative sensitivities of the non-tumor tissues to the electric fields is computed
in step 440. At step 450, the maximal allowed field intensity at the various areas is
determined and then based on the information inputted in steps 400 through 450, an
optimal field map is computed at step 460. At step 470, the selected isolects (those
present in the optimal field map) are computed as well as their position and
waveform and the voltage that is to be delivered to each isolect. In order to further
minimize the field map, the number of isolects is preferably reduced in step 480 to
produce a modified field map and then the deviation of the modified map from the
optimum is calculated. The calculated deviation is then compared to an inputted
threshold value and if the calculated deviation is below the inputted threshold, the
process of reducing the number of isolects is continued until the inputted threshold
is obtained. Once the inputted threshold is obtained, a signal is delivered to the
controller to activate the reduced number of isolects. At step 490, a signal is
generated and delivered to the function generating system (e.g., the generator that
produces the waveforms mentioned in step 470, such as an analog wave generator or
a digital one, e.g., a waveform generated by a PC and outputted through a digital to
analog converter) or the system is otherwise instructed to provide the selected
waveform and voltage to the isolects. The field that results from activation of the
isolects is monitored at step 510 and any errors are corrected. If any errors or
abnormalities are detected, the field is modified as necessary according to the
treatment protocol at step 520. The various algorithms that are used for the
necessary computations are described hereinafter. Since the signal that is delivered to each electrode (isolect) is a
voltage signal that has been specifically created for the specific electrode or for a
specific group of electrodes, the calculation of this voltage signal is an important
aspect of the present invention.
The voltages for the isolects are calculated as follows. Following the
anatomical definition of the areas to be treated, taking into consideration the specific
sensitivity of the different tissues to the TC fields and the target area, the desired
field distribution map is constructed, as described in the flow chart of Fig. 7. The
processor, which was fed the coordinates of all available isolects, now computes the
vector sum of the fields generated by each isolect at each point in time. The
computation can be made significantly faster in cases where an analytical expression
for the electric field originating from arbitrary placed electrodes is available. Such
a computation can be performed, for example, for the simple case; an isolect placed
on a muscle, or similar tissue, for which an analytical expression for the electric
field is:
Figure imgf000036_0001
Where Ri is the radius of the metallic part of the isolect, R2 is the
isolect radius including coating ε∞at and εmuscie are the dielectric constants of the
isolect coating and muscle, respectively and r is the distance between the electrodes
to the point where one wants to calculate the field. The fields generated in more
complex systems are usually computed by finite element methods, as described below.
Using this analytical expression, a series of iterations is initiated and
the controller 300, more specifically the CPU thereof, calculates the TC field, using
optimization methods, to optimize the voltage and the position of each electrode so
that one gets the desired spatial arrangement of the electric field. The computation
begins with a set of isolect locations and initial conditions, chosen arbitrary, or
based on a set of assumptions or previous experience. The field maps thus
generated are compared with the reference optimal map that was generated, as
described in the flow chart illustrated in Fig. 7. In the subsequent iterations, the
voltage and the position of the different isolects are changed and an optimal fit with
the optimal map is sought. In other words, one optimizes the correlation between
the calculated electric field (TC field) and the desired electric field (TC field). In
the above optimization method one can use, for example, the robust numeric
optimization method, known as the Nelder-Mead simplex method, as described in
Neider and Mead, Computer Journal Vol. 7, p. 308 (1965); Lagarias, J.C., J.A.
Reeds, M.H. Wright and P.E. Wright "Convergence Properties of the Neider-Mead
Simplex Method in Low Dimensions", SIAM Journal of Optimization, Vol. 9,
Number 1, pp. 112-147, 1986, all of which are hereby incorporated by reference in
their entirety. In addition, the calculations of the optimization method include the
method "Sequential Quadratic Programming", and this method is intended for
checking that the first one went fine. The references include Fletcher, R. and
M.J.D. Powell, "A Rapid Convergent Descent Method for Minimization,"
Computer Journal, Vol. 6, pp. 163-168; and Goldfarb, D., "A Family of Variable Metric Updates Derived by Variational Means:," Mathematics of Computing, Vol.
24, pp. 23-26, 1970, all of which are hereby incorporated by reference in their
entirety.
Now referring to Figs. 8-9 in which an article of clothing 600 in the
form of an undershirt is shown. Depending upon the precise location of the tumor
(target tissue), the undershirt 600 can be of an oversized type in that, as illustrated,
the undershirt 600 extends below the waist of the patient and in fact, it protrudes
around a portion of the user's upper legs (thighs); however, it will be appreciated
that the undershirt 600 can be of a more conventional type that lies above the waist.
The undershirt 600 has a predetermined number of electrodes 230 (e.g. , 20-100 in
number) that are arranged either in an orderly manner as shown (rows and columns)
or they can be arranged in a irregular pattern depending upon where the optimal
positioning of the electrodes 230 is determined to be. The electrodes 230 are held
in place by the undershirt construction, e.g., by adhesives or by stitching, etc. As
shown in Fig. 9, the electrodes 230 completely extend radially around the body of
the patient.
In Fig. 10, this type of procedure was carried out with the aim to
effectively focus the field at the selected area, which in this Figure is denoted by the
circle 610. In this example, random initialization of the electrode voltage and
positions were used.
In Fig. 11, the calculated optimal position of the electrodes, depicted
by circles 620, is illustrated around the tissue mass 630 where the electric field (TC field) intensity is minimal, as denoted by 640, while the intensity of the electric field
increases in the vicinity of the target (tissue mass) 630.
In yet another example of the procedure of calculating the isolect
placement that would give high field intensity at a number of skin locations, for
treatment of malignant melanoma's while having minimal field at the spine is
illustrated and described with reference to Figs. 12-18. In this example, one will
appreciate how the anatomy, the isolect structure and the tissue electric
characteristics are incorporated into the calculations. One of the advantages of
using an electric field to repress the prosperity of cells is that areas inside a human
being can be left outside of the electric field influence. According to this one
example, a model is constructed for a human having four electrodes around the mid
body portion and the electrodes are specifically arranged so that the electric field
around the human's spine is zero. The calculations are based on finite element mesh
(FEM) and the geometric model is described and illustrated with reference to Fig.
12. In Fig. 12, the axis units are in millimeters and the body is 0.5m width with a
0.35 thickness. Fig. 12 shows the location of the spine 650 relative to four
electrodes 660 that are spaced therearound. A skin boundary or layer of the patient
is generally shown at 670 with muscle 680 being shown as occupying the area
within the skin boundary 670 and around the spine 650.
Fig. 13 is also a geometric model illustrating an enlargement of the
area around one electrode 670 of Fig. 12 showing the interaction between the
electrode 670 and the skin layer 670. The axis units in Fig. 13 are in millimeters and in this exemplary embodiment, the electrode 660 includes a coating 662 that is
formed of PVC or potassium tantalate. In this example, the electrode 660 has a
diameter of about 10mm and the coating 662 that is disposed around an outer
surface 661 thereof has a thickness of about 0.1mm. The skin layer 670 has a
thickness of about 1mm. Table 1 sets forth the parameters for the materials that are
used in the calculations that are used with the geometric models of Figs. 12 and 13.
Table 1: Material Data
Figure imgf000040_0001
In all of the calculations for this example, the voltage between the
electrodes 660 was IV and the frequency of the sine voltage was lOOKHz.
In this example, the electrodes 660 are placed in a symmetric
formation such that the electric field in the middle of the body is zero. Fig. 14 is
photographic image of the electrodes 660 around the spine 650 illustrating the
electric field representation in the symmetric formation of the electrodes. Fig. 15 is another representation of the electric field; however, this representation of the
electric field is by arrows. As will be appreciated, only the electric field inside the
body is shown. As can be seen from both Figs. 14 and 15, the electric field is zero
in the middle of the body and is very high in the area of the spine 650. This is
unwanted since the presence of the electric field, near the spine 650 can be
potentially harmful. In Fig. 16, the electrodes 660 have been rearranged so that the
electric field is zero in the spine area 650 and not zero in the middle of the body.
Fig. 16 is a schematic illustration of the arrangement of the electrodes 660 that
causes a zero electric field in the area of the spine 650. Fig. 17 is a photographic
image of the electric field in an asymmetric formation of the electrodes and Fig. 18
is another representation of the electric field, similar to Fig. 15, in which the
electric field is represented by arrows and only the electric field inside the body is
drawn. As can be seen from Figs. 17 and 18, the asymmetric arrangement of the
electrodes causes a zero electric field in the area of the spine 650, while the field
outside the spine 650 is not zero.
Based on the above calculations, one will appreciate that a proper
arrangement of the electrodes can shape the electric field so that it becomes zero at
areas we choose, such as the spine area 650, in this example. In application, the
procedure can entail using a CT image to position the internal organs, calculate on-
line the electric field using the present methodology and automatically position the
electrodes on the patient's body so that an area that we do not want to harm will not
suffer from the presence of an electric field. The specifications of the apparatus 200 as a whole and its individual
components are largely influenced by the fact that at the frequency of the present TC
fields (50KHz - 500KHz), living systems behave according to their "Ohmic", rather
than their dielectric properties. The only elements in the apparatus 200 that behave
differently are the insulators of the isolects 230 (see Figs. 19-21). The isolects 200
consist of a conductor in contact with a dielectric that is in contact with the
conductive tissue thus forming a capacitor.
There are any number of different types of applications in which the
apparatus 200 or one of the others disclosed herein can be used. The following
applications are merely exemplary and not limiting of the number of different types
of applications which can be used. Fig. 19 illustrates an exemplary embodiment
where the isolects 230 are incorporated in a skin patch 700. The skin patch 700 can
be a self-adhesive flexible patch with one or more pairs of isolects 230. The patch
700 includes internal insulation 710 (formed of a dielectric material) and the
external insulation 260 and is applied to skin surface 701 that contains a tumor 703
either on the skin surface 701 or slightly below the skin surface 701. Tissue is
generally indicated at 705. To prevent the potential drop across the internal
insulation 710 to dominate the system, the internal insulation 710 must have a
relatively high capacity. This can be achieved by a large surface area; however, this
may not be desired as it will result in the spread of the field over a large area (e.g. ,
an area larger than required to treat the tumor). Alternatively, the internal
insulation 710 can be made very thin and/or the internal insulation 710 can be of a
high dielectric constant. As the skin resistance between the electrodes (labeled as A and E in Fig. 6) is normally significantly higher than that of the tissue (labeled as C
in Fig. 6) underneath it (1-10 KΩ vs. 0.1-1KΩ), most of the potential drop beyond
the isolects occurs there. To accommodate for these impedances (Z), the
characteristics of the internal insulation 710 (labeled as B and D in Fig. 6) should be
such that they have impedance preferably under 100KΩ at the frequencies of the
present TC fields (e.g., 50KHz to 500KHz). For example, if it is desired for the
impedance to be about 10K Ohms or less, such that over 1 % of the applied voltage
falls on the tissues, for isolects with a surface area of 10 mm2, at frequencies of
200KHz, the capacity should be on the order of 10"10 F, which means that using
standard insulations with a dielectric constant of 2-3, the thickness of the insulating
layer 710 should be about 50-100 microns. An internal field 10 times stronger
would be obtained with insulators with a dielectric constant of about 20-50.
Figs. 20 and 21 illustrate a second type of treatment using the isolects
230, namely electric field generation by internal isolects 230. A body to which the
isolects 230 are implanted is generally indicated at 711 and includes a skin surface
713 and a tumor 715. In this embodiment, the isolects 230 can have the shape of
plates, wires or other shapes that can be inserted subcutaneously or a deeper
location within the body 711 so as to generate an appropriate field at the target area
(tumor 715). Fig. 22 illustrates the various constructions of the isolects 230,
including the use of internal insulation 710, a filler or gel 270 and external insulation 260.
It will also be appreciated that the mode of isolects application is not restricted to the above descriptions. In the case of tumors in internal organs, for
example, liver, lung, etc., the distance between each member of the pair of isolects
230 can be large. The pairs can even by positioned opposite sides of a torso 720, as
illustrated in Fig. 23. The arrangement of the isolects 230 in Fig. 23 is particularly
useful for treating a tumor 730 associated with lung cancer or gastro-intestinal
tumors. In this embodiment, the electric fields (TC fields) spread in a wide fraction
of the body.
In order to achieve the desirable features of the isolects 230, the
dielectric coating of each should be very thin, for example from between 1-50
microns. Since the coating is so thin, the isolects 230 can easily be damaged
mechanically. This problem can be overcome by adding a protective feature to the
isolect' s structure so as to provide desired protection from such damage. For
example, the isolect 230 can be coated, for example, with a relatively loose net 340
that prevents access to the surface but has only a minor effect on the effective
surface area of the isolect 230 (i.e. , the capacity of the isolects 230 (cross section
presented in Fig. 24B). The loose net 340 does not effect the capacity and ensures
good contact with the skin, etc. The loose net 340 can be formed of a number of
different materials; however, in one exemplary embodiment, the net 340 is formed
of nylon, polyester, cotton, etc. Alternatively, a very thin conductive coating 350
can be applied to the dielectric portion (insulating layer) of the isolect 230. One
exemplary conductive coating is formed of a metal and more particularly of gold.
The thickness of the coating 350 depends upon the particular application and also on
the type of material used to form the coating 350; however, when gold is used, the coating has a thickness from about 0.1 micron to about 0.1 mm.
In order to avoid overheating of the treated tissues, a selection of
materials and field parameters is needed. The isolects insulating material should
have minimal dielectric losses at the frequency ranges to be used during the
treatment process. This factor can be taken into consideration when choosing the
particular frequencies for the treatment. The direct heating of the tissues will most
likely be dominated by the heating due to current flow (given by the PR product).
In addition, the isolect (insulated electrode) 230 and its surroundings should be
made of materials that facilitate heat losses and its general structure should also
facilitate head losses, i.e., minimal structures that block heat dissipation to the
surroundings (air) as well as high heat conductivity.
The effectiveness of the treatment can be enhanced by an arrangement
of isolects 230 that focuses the field at the desired target while leaving other
sensitive areas in low field density (i.e., protected areas). The proper placement of
the isolects 230 over the body can be maintained using any number of different
techniques, including using a suitable piece of clothing that keeps the isolects at the
appropriate positions. Fig. 25 illustrates such an arrangement in which an area
labeled as "P" represents a protected area. The lines of field force do not penetrate
this protected area and the field there is much smaller than near the isolects 230
where target areas can be located and treated well. In contrast, the field intensity
near the four poles is very high.
The present inventor has thus uncovered that electric fields having particular properties can be used to destroy dividing cells or tumors when the
electric fields are applied to using an electronic device. More specifically, these
electric fields fall into a special intermediate category, namely bio-effective fields
that have no meaningful stimulatory and no thermal effects, and therefore overcome
the disadvantages that were associated with the application of conventional electric
fields to a body. It will also be appreciated that the present apparatus can further
include a device for rotating the TC field relative to the living tissue. For example
and according to one embodiment, the alternating electric potential applies to the
tissue being treated is rotated relative to the tissue using conventional devices, such
as a mechanical device that upon activation, rotates various components of the
present system.
Moreover and according to yet another embodiment, the TC fields
are applied to different pairs of the insulated electrodes 230 in a consecutive
manner. In other words, the generator 210 and the control system thereof can be
arranged so that signals are sent at periodic intervals to select pairs of insulated
electrodes 230, thereby causing the generation of the TC fields of different
directions by these insulated electrodes 230. Because the signals are sent at select
times from the generator to the insulated electrodes 230, the TC fields of changing
directions are generated consecutively by different insulated electrodes 230. This
arrangement has a number of advantages and is provided in view of the fact that the
TC fields have maximal effect when they are parallel to the axis of cell division.
Since the orientation of cell division is in most cases random, only a fraction of the
dividing cells are affected by any given field. Thus, using fields of two or more orientations increases the effectiveness since it increases the chances that more
dividing cells are affected by a given TC field.
Turning now to Fig. 26 in which an article of clothing 800 according
to one exemplary embodiment is illustrated. More specifically, the article of
clothing 800 is in the form of a hat or cap or other type of clothing designed for
placement on a head of a person. For purposes of illustration, a head 802 is shown
with the hat 800 being placed thereon and against a skin surface 804 of the head
802. An intra-cranial tumor or the like 810 is shown as being formed within the
head 802 underneath the skin surface 804 thereof. The hat 800 is therefore intended
for placement on the head 802 of a person who has a tumor 810 or the like.
Unlike the various embodiments illustrated in the other Figures where
the insulated electrodes 230 are arranged in a more or less planar arrangement since
they are placed either on a skin surface or embedded within the body underneath it,
the insulated electrodes 230 in this embodiment are specifically contoured and
arranged for a specific application. The treatment of intra-cranial tumors or other
lesions or the like typically requires a treatment that is of a relatively long duration,
e.g., days to weeks, and therefore, it is desirable to provide as much comfort as
possible to the patient. The hat 800 is specifically designed to provide comfort
during the lengthy treatment process while not jeopardizing the effectiveness of the
treatment.
According to one exemplary embodiment, the hat 800 includes a
predetermined number of insulated electrodes 230 that are preferably positioned so as to produce the optimal TC fields at the location of the tumor 810. The lines of
force of the TC field are generally indicated at 820. As can be seen in Fig. 26, the
tumor 810 is positioned within these lines of force 820. As will be described in
greater detail hereinafter, the insulated electrodes 230 are positioned within the hat
800 such that a portion or surface thereof is free to contact the skin surface 804 of
the head 802. In other words, when the patient wears the hat 800, the insulated
electrodes 230 are placed in contact with the skin surface 804 of the head 802 in
positions that are selected so that the TC fields generated thereby are focused at the
tumor 810 while leaving surrounding areas in low density. Typically, hair on the
head 802 is shaved in selected areas to permit better contact between the insulated
electrodes 230 and the skin surface 804; however, this is not critical.
The hat 800 preferably includes a mechanism 830 that applies or
force to the insulated electrodes 230 so that they are pressed against the skin surface
802. For example, the mechanism 830 can be of a biasing type that applies a
biasing force to the insulated electrodes 230 to cause the insulated electrodes 230 to
be directed outwardly away from the hat 800. Thus, when the patient places the hat
800 on his/her head 802, the insulated electrodes 230 are pressed against the skin
surface 804 by the mechanism 830. The mechanism 830 can slightly recoil to
provide a comfortable fit between the insulated electrodes 230 and the head 802. In
one exemplary embodiment, the mechanism 830 is a spring based device that is disposed within the hat 800 and has one section that is coupled to and applies a force
against the insulated electrodes 230, as described below with reference to Figs. 27
and 28. As with the prior embodiments, the insulated electrodes 230 are
coupled to the generator 210 by means of conductors 220. The generator 210 can
be either disposed within the hat 800 itself so as to provide a compact, self-
sufficient, independent system or the generator 210 can be disposed external to the
hat 800 with the conductors 220 exiting the hat 800 through openings or the like and
then running to the generator 210. When the generator 210 is disposed external to
the hat 800, it will be appreciated that the generator 210 can be located in any
number of different locations, some of which are in close proximity to the hat 800
itself, while others can be further away from the hat 800. For example, the
generator 210 can be disposed within a carrying bag or the like (e.g. , a bag that
extends around the patient's waist) which is worn by the patient or it can be strapped
to an extremity or around the torso of the patient. The generator 210 can also be
disposed in a protective case that is secured to or carried by another article of
clothing that is worn by the patient. For example, the protective case can be
inserted into a pocket of a sweater, etc. Fig. 26 illustrates an embodiment where the
generator 210 is incorporated directly into the hat 800.
Turning now to Figs. 27 and 28, in one exemplary embodiment, a
number of insulated electrodes 230 along with the mechanism 830 are preferably
formed as an independent unit, generally indicated at 840, that can be inserted into
the hat 800 and electrically connected to the generator (not shown) via the
conductors (not shown). By providing these members in the form of an independent
unit, the patient can easily insert and/or remove the units 840 from the hat 800 when they may need cleaning, servicing and/or replacement. In this embodiment, the hat 800 is constructed to include select areas
850 that are formed in the hat 800 to receive and hold the units 840. For example
and as illustrated in Fig. 27, each area 850 is in the form of an opening (pore) that is
formed within the hat 800. The unit 840 has a body 842 and includes the
mechanism 830 and one or more insulated electrodes 230. The mechanism 830 is
arranged within the unit 840 so that a portion thereof (e.g. , one end thereof) is in
contact with a face of each insulated electrode 230 such that the mechanism 830
applies a biasing force against the face of the insulated electrode 230. Once the unit
840 is received within the opening 850, it can be securely retained therein using any
number of conventional techniques, including the use of an adhesive material or by
using mechanical means. For example, the hat 800 can include pivotable clip
members that pivot between an open position in which the opening 850 is free and a
closed position in which the pivotable clip members engage portions (e.g.,
peripheral edges) of the insulated electrodes to retain and hold the insulated
electrodes 230 in place. To remove the insulated electrodes 230, the pivotable clip
members are moved to the open position. In the embodiment illustrated in Fig. 28,
the insulated electrodes 230 are retained within the openings 850 by an adhesive
element 860 which in one embodiment is a two sided self-adhesive rim member that
extends around the periphery of the insulated electrode 230. In other words, a
protective cover of one side of the adhesive rim 860 is removed and it is applied around the periphery of the exposed face of the insulated electrode 230, thereby
securely attaching the adhesive rim 860 to the hat 800 and then the other side of the
adhesive rim 860 is removed for application to the skin surface 804 in desired locations for positioning and securing the insulated electrode 230 to the head 802
with the tumor being positioned relative thereto for optimization of the TC fields.
Since one side of the adhesive rim 860 is in contact with and secured to the skin
surface 840, this is why it is desirable for the head 802 to be shaved so that the
adhesive rim 860 can be placed flushly against the skin surface 840.
The adhesive rim 860 is designed to securely attach the unit 840
within the opening 850 in a manner that permits the unit 840 to be easily removed
from the hat 800 when necessary and then replaced with another unit 840 or with
the same unit 840. As previously mentioned, the unit 840 includes the biasing
mechanism 830 for pressing the insulated electrode 230 against the skin surface 804
when the hat 800 is worn. The unit 840 can be constructed so that side opposite the
insulated electrode 230 is a support surface formed of a rigid material, such as
plastic, so that the biasing mechanism 830 (e.g., a spring) can be compressed
therewith under the application of force and when the spring 830 is in a relaxed
state, the spring 830 remains in contact with the support surface and the applies a
biasing force at its other end against the insulated electrode 230. The biasing
mechanism 830 (e.g., spring) preferably has a contour corresponding to the skin
surface 804 so that the insulated electrode 230 has a force applied thereto to permit
the insulated electrode 230 to have a contour complementary to the skin surface 804,
thereby permitting the two to seat flushly against one another. While the
mechanism 830 can be a spring, there are a number of other embodiments that can
be used instead of a spring. For example, the mechanism 830 can be in the form of
an elastic material, such as a foam rubber, a foam plastic, or a layer containing air bubbles, etc.
The unit 840 has an electric connector 870 that can be hooked up to a
corresponding electric connector, such as a conductor 220, that is disposed within
the hat 800. The conductor 220 connects at one end to the unit 840 and at the other
end is connected to the generator 210. The generator 210 can be incorporated
directly into the hat 800 or the generator 210 can be positioned separately (remotely)
on the patient or on a bedside support, etc.
As previously discussed, a coupling agent, such as a conductive gel,
is preferably used to ensure that an effective conductive environment is provided
between the insulated electrode 230 and the skin surface 804. Suitable gel materials
have been disclosed hereinbefore in the discussion of earlier embodiments. The
coupling agent is disposed on the insulated electrode 230 and preferably, a uniform
layer of the agent is provided along the surface of the electrode 230. One of the
reasons that the units 840 need replacement at periodic times is that the coupling
agent needs to be replaced and/or replenished. In other words, after a
predetermined time period or after a number of uses, the patient removes the units
840 so that the coupling agent can be applied again to the electrode 230.
Figs. 29 and 30 illustrate another article of clothing which has the
insulated electrodes 230 incorporated as part thereof. More specifically, a bra or
the like 900 is illustrated and includes a body that is formed of a traditional bra
material, generally indicated at 905, to provide shape, support and comfort to the
wearer. The bra 900 also includes a fabric support layer 910 on one side thereof. The support layer 910 is preferably formed of a suitable fabric material that is
constructed to provide necessary and desired support to the bra 900.
Similar to the other embodiments, the bra 900 includes one or more
insulated electrodes 230 disposed within the bra material 905. The one or more
insulated electrodes are disposed along an inner surface of the bra 900 opposite the
support 910 and are intended to be placed proximate to a tumor or the like that is
located within one breast or in the immediately surrounding area. As with the
previous embodiment, the insulated electrodes 230 in this embodiment are
specifically constructed and configured for application to a breast or the immediate
area. Thus, the msulated electrodes 230 used in this application do not have a
planar surface construction but rather have an arcuate shape that is complementary
to the general curvature found in a typical breast.
A lining 920 is disposed across the insulated electrodes 230 so as to
assist in retaining the insulated electrodes in their desired locations along the inner
surface for placement against the breast itself. The lining 920 can be formed of any
number of thin materials that are comfortable to wear against one's skin and in one
exemplary embodiment, the lining 920 is formed of a fabric material.
The bra 900 also preferably includes a biasing mechanism 1000 as in
some of the earlier embodiments. The biasing mechanism 1000 is disposed within
the bra material 905 and extends from the support 910 to the insulated electrode 230
and applies a biasing force to the insulated electrode 230 so that the electrode 230 is
pressed against the breast. This ensures that the insulated electrode 230 remains in contact with the skin surface as opposed to lifting away from the skin surface,
thereby creating a gap that results in a less effective treatment since the gap
diminishes the efficiency of the TC fields. The biasing mechanism 1000 can be in
the form of a spring arrangement or it can be an elastic material that applies the
desired biasing force to the insulated electrodes 230 so as to press the insulated
electrodes 230 into the breast. In the relaxed position, the biasing mechanism 1000
applies a force against the insulated electrodes 230 and when the patient places the
bra 900 on their body, the insulated electrodes 230 are placed against the breast
which itself applies a force that counters the biasing force, thereby resulting in the
insulated electrodes 230 being pressed against the patient's breast. In the exemplary
embodiment that is illustrated, the biasing mechanism 1000 is in the form of springs
that are disposed within the bra material 905.
A conductive gel 1010 can be provided on the insulated electrode 230
between the electrode and the lining 920. The conductive gel layer 1010 is formed
of materials that have been previously described herein for performing the functions
described above.
An electric connector 1020 is provided as part of the insulated
electrode 230 and electrically connects to the conductor 220 at one end thereof, with
the other end of the conductor 220 being electrically connected to the generator 210.
In this embodiment, the conductor 220 runs within the bra material 905 to a location where an opening is formed in the bra 900. The conductor 220 extends
through this opening and is routed to the generator 210, which in this embodiment is disposed in a location remote from the bra 900. It will also be appreciated that the
generator 210 can be disposed within the bra 900 itself in another embodiment. For
example, the bra 900 can have a compartment formed therein which is configured to
receive and hold the generator 210 in place as the patient wears the bra 900. In this
arrangement, the compartment can be covered with a releasable strap that can open
and close to permit the generator 210 to be inserted therein or removed therefrom.
The strap can be formed of the same material that is used to construct the bra 900 or
it can be formed of some other type of material. The strap can be releasably
attached to the surrounding bra body by fastening means, such as a hook and loop
material, thereby permitting the patient to easily open the compartment by
separating the hook and loop elements to gain access to the compartment for either
inserting or removing the generator 210.
The generator 210 also has a connector 211 for electrical connection
to the conductor 220 and this permits the generator 210 to be electrically connected
to the insulated electrodes 230.
As with the other embodiments, the insulated electrodes 230 are
arranged in the bra 900 to focus the electric field (TC fields) on the desired target
(e.g., a tumor). It will be appreciated that the location of the insulated electrodes
230 within the bra 900 will vary depending upon the location of the tumor. In other
words, after the tumor has been located, the physician will then devise an
arrangement of insulated electrodes 230 and the bra 900 is constructed in view of
this arrangement so as to optimize the effects of the TC fields on the target area (tumor). The number and position of the insulated electrodes 230 will therefore
depend upon the precise location of the tumor or other target area that is being
treated. Because the location of the insulated electrodes 230 on the bra 900 can vary
depending upon the precise application, the exact size and shape of the insulated
electrodes 230 can likewise vary. For example, if the insulated electrodes 230 are
placed on the bottom section of the bra 900 as opposed to a more central location,
the insulated electrodes 230 will have different shapes since the shape of the breast
(as well as the bra) differs in these areas.
Fig. 31 illustrates yet another embodiment in which the insulated
electrodes 230 are in the form of internal electrodes that are incorporated into in the
form of a probe or catheter 1100 that is configured to enter the body through a
natural pathway, such as the urethra, vagina, etc. In this embodiment, the insulated
electrodes 230 are disposed on an outer surface of the probe 1100 and along a length
thereof. The conductors 220 are electrically connected to the electrodes 230 and run
within the body of the probe 1100 to the generator 210 which can be disposed
within the probe body or the generator 210 can be disposed independent of the
probe 1100 in a remote location, such as on the patient or at some other location
close to the patient.
Alternatively, the probe 1100 can be configured to penetrate the skin
surface or other tissue to reach an internal target that lies within the body. For
example, the probe 1100 can penetrate the skin surface and then be positioned
adjacent to or proximate to a tumor that is located within the body. In these embodiments, the probe 1100 is inserted through the natural
pathway and then is positioned in a desired location so that the insulated electrodes
230 are disposed near the target area (i.e., the tumor). The generator 210 is then
activated to cause the insulated electrodes 230 to generate the TC fields which are
applied to the tumor for a predetermined length of time. It will be appreciated that
the illustrated probe 1100 is merely exemplary in nature and that the probe 1100 can
have other shapes and configurations so long as they can perform the intended
function. Preferably, the conductors (e.g., wires) leading from the insulated
electrodes 230 to the generator 210 are twisted or shielded so as not to generate a
field along the shaft.
It will further be appreciated that the probes can contain only one
insulated electrode while the other can be positioned on the body surface. This
external electrode should be larger or consist of numerous electrodes so as to result
in low lines of force -current density so as not to affect the untreated areas. In fact,
the placing of electrodes should be designed to minimize the field at potentially
sensitive areas.
Fig. 32 illustrates yet another embodiment in which a high standing
collar member 1200 (or necklace type structure) can be used to treat thyroid,
parathyroid, laryngeal lesions, etc. Fig. 32 illustrates the collar member 1200 in an
unwrapped, substantially flat condition. In this embodiment, the insulated
electrodes 230 are incorporated into a body 1210 of the collar member 1200 and are
configured for placement against a neck area of the wearer. The insulated electrodes 230 are coupled to the generator 210 according to any of the manner
described hereinbefore and it will be appreciated that the generator 210 can be
disposed within the body 1210 or it can be disposed in a location external to the
body 1210. The collar body 1210 can be formed of any number of materials that
are traditionally used to form collars 1200 that are disposed around a person's neck.
As such, the collar 1200 preferably includes a means 1220 for adjusting the collar
1200 relative to the neck. For example, complementary fasteners (hook and loop
fasteners, buttons, etc.) can be disposed on ends of the collar 1200 to permit
adjustment of the collar diameter. It will be appreciated that one can extend this
exemplary structure to accommodate any tubular part of the body, e.g. , a limb, etc.
Figs. 33 and 34 illustrate yet another embodiment of the present
device. In Fig. 33, a pair of electrodes 230 are arranged about a torso 1300. The
electrodes 230 are operated in the same manner as was previously described and in
this embodiment, the electrodes 230 are arranged so that the electric field passes
through the heart and its surrounding area.
The present inventor has thus appreciated that the above described
TC fields that stop cell proliferation can be used to prevent restenosis of arteries
after angioplasty, with or without introduction of stents. This also applies for other
body tubing, such as urethra. The coronary restenosis which follows 20-30% of
stenting, etc., is a major problem. The restenosis is due to the cellular reaction of
the arterial wall and the resulting cell proliferation. This proliferation grows into
the artery from its ends and on top of it, there is sedimentation, etc. , that occludes the artery. The conditions for the effect of the TC fields are good as the stent is
usually a bare metal conductor (but not necessarily) that will result in field
intensification exactly where it is needed. The TC fields should be applied for 3-8
weeks to prevent the stenosis.
As shown in Figs. 33 and 34, the electrodes 230 are arranged about
the torso 1300 so that the TC fields, indicated by field lines 1310, passes through
the heart region 1320. A coronary artery 1330 is illustrated within the heart region
1320 and within the TC fields. One or more stents 1340 are disposed within the
coronary artery 1330 as part of the surgical procedure. One of the results of the
angioplasty and mainly due to the presence of the stents 1340 is a proliferation of a
mass of cells 1350 that is located along the artery wall. Since the stent 1340 acts as
a conductor, the area around the stent 1340 is an area of high density electric field
due to the presence of the stent 1340. The stent 1340 does not necessarily have to be a bare metal conductor and the present method of treatment can be used without
stents 1340 so long as the mass of proliferating cells 1350 is disposed within the
area of the high density electric field.
Thus, the construction of the present devices are particularly well
suited for applications where the devices are incorporated into articles of clothing to
permit the patient to easily wear a traditional article of clothing while at the same
time the patient undergoes treatment. In other words, an extra level of comfort can
be provided to the patient and the effectiveness of the treatment can be increased by
incorporating some or all of the device components into the article of clothing. The precise article of clothing that the components are incorporated into will obviously
vary depending upon the target area of the living tissue where tumor, lesion or the
like exists. For example, if the target area is in the testicle area of a male patient,
then an article of clothing in the form of a sock-like structure or wrap can be
provided and is configured to be worn around the testicle area of the patient in such
a manner that the insulated electrodes thereof are positioned relative to the tumor
such that the TC fields are directed at the target tissue. The precise nature or form
of the article of clothing can vary greatly since the device components can be
incorporated into most types of articles of clothing and therefore, can be used to
treat any number of different areas of the patient's body where a condition may be
present.
The present invention is thus for an apparatus and method for
optimizing the selective destruction of dividing cells by calculating the spatial and
temporal distribution of the electric fields for optimal treatment of a specific patient
with a specific tumor, taking into account its location and characteristics of all
components of the system. An optimal field map is generated by calculating and
computing an electric field in terms of its strength and other characteristics for a
given arrangement of electrodes and based on other inputted information, such as
tumor type. This calculation can be done by a controller or other device, such as an
integrated personal computer, and additional calculations are conducted for different
arrangement of electrodes relative to the target area (tumor) and/or different
voltages for the electrodes. Standard optimization methods are used to determine
the optimal minimal field map. It is therefore desirable that the optimum field map not only includes a maximum electric field at the target area (tumor) but also that
there be a maximal field strength difference between the electric field at the target
tissue and the surrounding tissue that is to be protected. It will therefore be
appreciated that the optimal field may not necessarily be one that has the highest
electric field strength focused at the targeted area but it may be one where the
electric field strength is less but the difference in field strength between the target
area and the surrounding areas is at a maximum. In other words, the present
method optimizes the correlation between the calculated electric field and the
desired electric field (the previously calculated optimal field map). For
optimization, standard techniques can be used, such as the Neider-Mead simplex
method.
As used herein, the term "tumor" refers to a malignant tissue
comprising transformed cells that grow uncontrollably. Tumors include leukemias,
lymphomas, myelomas, plasmacytomas, and the like; and solid tumors. Examples
of solid tumors that can be treated according to the invention include sarcomas and
carcinomas such as, but not limited to: fibrosarcoma, myxosarcoma, liposarcoma,
chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma,
lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma,
Ewing' s tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic
cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma,
basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland
carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma,
medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor,
cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma,
bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma,
craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic
neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, and
retinoblastoma. Because each of these tumors undergoes rapid growth, any one can
be treated in accordance with the invention. The invention is particularly
advantageous for treating brain tumors, which are difficult to treat with surgery and
radiation, and often inaccessible to chemotherapy or gene therapies. In addition, the
present invention is suitable for use in treating skin and breast tumors because of the
ease of localized treatment provided by the present invention.
In addition, the present invention can control uncontrolled growth
associated with non-malignant or pre-malignant conditions, and other disorders
involving inappropriate cell or tissue growth by application of an electric field in
accordance with the invention to the tissue undergoing inappropriate growth. For
example, it is contemplated that the invention is useful for the treatment of
arterio venous (AV) malformations, particularly in intracranial sites. The invention
may also be used to treat psoriasis, a dermatologic condition that is characterized by
inflammation and vascular proliferation; and benign prostatic hypertrophy, a
condition associated with inflammation and possibly vascular proliferation.
Treatment of other hyperproliferative disorders is also contemplated.
Furthermore, undesirable fibroblast and endothelial cell proliferation associated with wound healing, leading to scar and keloid formation after surgery or
injury, and restenosis after angioplasty or placement of coronary stents can be
inhibited by application of an electric field in accordance with the present invention.
The non-invasive nature of this invention makes it particularly desirable for these
types of conditions, particularly to prevent development of internal scars and
adhesions, or to inhibit restenosis of coronary, carotid, and other important arteries.
Thus, the present invention provides an effective, simple method of
selectively destroying dividing cells, e.g., tumor cells and parasitic organisms,
while non-dividing cells or organisms are left affected by application of the. method
on living tissue containing both types of cells or organisms. Thus, unlike many of
the conventional methods, the present invention does not damage the normal cells or
organisms. In addition, the present invention does not discriminate based upon cell
type (e.g., cells having differing sizes) and therefore may be used to treat any
number of types of sizes having a wide spectrum of characteristics, including
varying dimensions.
It will be appreciated by persons skilled in the art that the present
invention is not limited to the embodiments described thus far with reference to the
accompanying drawing. Rather the present invention is limited only by the
following claims.

Claims

WHAT IS CLAIMED IS:
1. A method for optimizing the selective destruction of dividing cells in a malcontroUed cell growth using a device that subjects the cell growth to an alternating electric field, wherein passage of the electric field through the dividing cells in late anaphase or telophase transforms the electric field into a non- homogeneous electric field with an increased density in a region of the dividing cells, the optimization method comprising the steps of: computing an optimal field map of the positions of electrodes relative to the malcontroUed cell growth in a target area; arranging the electrodes according to a select pattern relative to the malcontroUed cell growth and computing a vector sum of electric fields to generate an electric field map; comparing the electric field map to the optimal field map; changing one of a delivered voltage to the electrodes and a location of the electrodes and computing a vector sum of electric fields to generate an electric field map for the electrodes; optimizing a correlation between the calculated electric field map and the optimal field map, wherein the optimization step takes into account the electrode voltage, wave shape and position of each electrode; and wherein the electric field is computed in accordance with the expression:
Figure imgf000064_0001
where Ri is the radius of a conductive part of the electrode; R2 is the electrode radius including a coating disposed on the electrode; and ε∞at and εtissue are the dielectric constants of the electrode coating and tissue, respectively and r is the distance between the electrodes to the point where one wants to calculate the electric field.
2. The method of claim 1 , wherein the step of computing an optimal field map includes the steps of:
(a) inputting characteristics of tissue cells in the target area;
(b) inputting characteristics of the malcontroUed tissue cells in the target area; (c) inputting anatomical characteristics of the target area;
(d) computing a threshold field intensity in the malcontroUed cell growth;
(e) computing relative sensitivities of surrounding healthy tissue to the electric fields; (f) computing a maximal allowed field intensity at predetermined locations; and
(g) computing the optimal field map on the basis of the information generated in steps (a) to (f).
3. The method of claim 1, wherein device includes: a first insulated electrode having a first conductor; a second insulated electrode having a second conductor; and an electric field source connected to the first and second insulated electrodes for applying the alternating electric field across the first and second conductors to create a condition in the dividing cells that encourages the destruction thereof.
4. The method of claim 3, wherein the first electrode includes a first dielectric member that is in contact with the first conductor, the first dielectric member for placement against the living tissue to form a capacitor and wherein the second electrode includes a second dielectric member that is in contact with the second conductor, the second dielectric member for placement against the living tissue to form a capacitor.
5. The method of claim 1, wherein the alternating electric field has a frequency of between about 50KHz to about 500KHz.
6. The method of claim 1, wherein the alternating electric field has a frequency of between about lOOKHz to about 300KHz.
7. The method of claim 3, wherein the electric field source comprises a generator that generates an alternating voltage waveform at frequencies between about 50KHz to about 500KHz.
8. The method of claim 7, including the step of: activating the first and second electrodes by the alternating voltage waveform.
9. The method of claim 1 , wherein the coating of the electrode comprises a potassium tantalate coating.
10. The method of claim 1, wherein the step of optimizing a correlation comprises the step of: applying a robust numeric optimization method to optimize the correlation between the calculated electric field map and the optimal field map.
11. The method of claim 1 , wherein the select pattern is one of a symmetric pattern and a non-symmetric pattern.
12. The method of claim 1, wherein the step of computing a vector sum comprises the steps of: feeding coordinates of all available electrodes; and computing the vector sum of the fields generated by each electrode at each point in time.
13. The method of claim 1, wherein the optimization step includes balancing the strength of the electric field at the malcontroUed cell growth and maximizing a difference between electric field strength at the malcontroUed cell growth and the electric field strength at surrounding healthy tissue.
14. The method of claim 1, wherein the tissue is muscle tissue and εtissue equals εmuscie.
15. A method to prevent restenosis of arteries after angioplasty, the method comprising the steps of: providing an apparatus having: a first insulated electrode; a second insulated electrode; and an electric field source for applying an alternating electric field across the first and second conductors; positioning the first and second insulated electrodes in relation to at least one mass of proliferating cells within at least one artery; and subjecting the one or more masses of proliferating cells to an alternating electric field, wherein passage of the electric field through the proliferating cells in late anaphase or telophase transforms the electric field into a non-homogeneous electric field that produces an increased density electric field in a region of the cells and induces a structural change in the cells resulting in destruction thereof, wherein subjecting the living tissue to the alternating electric field comprises applying an alternating electric potential having a frequency of between about 50KHz to about 500KHz.
16. The method of claim 14, wherein positioning the first and second insulated electrodes comprises: placing the first and second electrodes against a chest wall and positioning the electrodes so that the heart and the targeted artery fall within a high density region of the electric field.
17. The method of claim 14, further including the step of: placing a stent within the artery, the mass of proliferating cells growing at or near the stent.
18. The method of claim 16, wherein the stent comprises a conductive stent.
19. The method of claim 14, wherein the alternating electric potential has a frequency of between about lOOKHz to about 300KHz.
PCT/IB2004/000918 2002-10-16 2004-03-26 Apparatus and method for optimizing tumor treatment efficiency by electric fields WO2004084747A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/204,334 US7333852B2 (en) 2000-02-17 2001-02-16 Method and apparatus for destroying dividing cells
US10/402,327 US7146210B2 (en) 2000-02-17 2003-03-28 Apparatus and method for optimizing tumor treatment efficiency by electric fields
US10/402,327 2003-03-28

Publications (1)

Publication Number Publication Date
WO2004084747A2 true WO2004084747A2 (en) 2004-10-07

Family

ID=33096820

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/000918 WO2004084747A2 (en) 2002-10-16 2004-03-26 Apparatus and method for optimizing tumor treatment efficiency by electric fields

Country Status (2)

Country Link
US (1) US7146210B2 (en)
WO (1) WO2004084747A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10792495B2 (en) 2016-12-01 2020-10-06 Thimble Bioelectronics, Inc. Neuromodulation device and method for use

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364577B2 (en) 2002-02-11 2008-04-29 Sherwood Services Ag Vessel sealing system
US7137980B2 (en) 1998-10-23 2006-11-21 Sherwood Services Ag Method and system for controlling output of RF medical generator
US7901400B2 (en) 1998-10-23 2011-03-08 Covidien Ag Method and system for controlling output of RF medical generator
US8175698B2 (en) 2000-02-17 2012-05-08 Novocure Ltd. Treating bacteria with electric fields
US6868289B2 (en) * 2002-10-02 2005-03-15 Standen Ltd. Apparatus for treating a tumor or the like and articles incorporating the apparatus for treatment of the tumor
EP2335776A1 (en) 2000-02-17 2011-06-22 Yoram Palti Method and apparatus for destroying dividing cells
US8447395B2 (en) * 2000-02-17 2013-05-21 Novocure Ltd Treating bacteria with electric fields
US7089054B2 (en) * 2002-10-02 2006-08-08 Standen Ltd. Apparatus and method for treating a tumor or the like
US7136699B2 (en) * 2002-10-02 2006-11-14 Standen, Ltd. Apparatus for destroying dividing cells
US7044948B2 (en) 2002-12-10 2006-05-16 Sherwood Services Ag Circuit for controlling arc energy from an electrosurgical generator
DE10260149A1 (en) * 2002-12-20 2004-07-01 BSH Bosch und Siemens Hausgeräte GmbH Device for determining the conductivity of laundry, clothes dryer and method for preventing layer formation on electrodes
EP1617776B1 (en) 2003-05-01 2015-09-02 Covidien AG System for programing and controlling an electrosurgical generator system
WO2005050151A1 (en) 2003-10-23 2005-06-02 Sherwood Services Ag Thermocouple measurement circuit
US7396336B2 (en) 2003-10-30 2008-07-08 Sherwood Services Ag Switched resonant ultrasonic power amplifier system
US7131860B2 (en) 2003-11-20 2006-11-07 Sherwood Services Ag Connector systems for electrosurgical generator
US20100016929A1 (en) * 2004-01-22 2010-01-21 Arthur Prochazka Method and system for controlled nerve ablation
AU2005205853B2 (en) 2004-01-22 2011-01-27 2249020 Alberta Ltd. Method of routing electrical current to bodily tissues via implanted passive conductors
JP4750784B2 (en) 2004-04-23 2011-08-17 ノヴォキュアー・リミテッド Treatment of tumors by electric fields of different frequencies
US7628786B2 (en) 2004-10-13 2009-12-08 Covidien Ag Universal foot switch contact port
ES2663779T3 (en) * 2004-12-07 2018-04-17 Novocure Limited Electrodes to apply an electric field in vivo for a period of time
WO2006085150A2 (en) * 2004-12-27 2006-08-17 Standen Ltd. Treating a tumor or the like with electric fields at different orientations
DE102005007851A1 (en) * 2005-02-21 2006-08-24 Siemens Ag Irradiation apparatus for irradiating a living organism with electromagnetic radiation to affect the biologic structure of the organism
US9474564B2 (en) 2005-03-31 2016-10-25 Covidien Ag Method and system for compensating for external impedance of an energy carrying component when controlling an electrosurgical generator
EP1899002A1 (en) * 2005-06-28 2008-03-19 Bioness Development, Llc Improvements to an implant, system and method using implanted passive conductors for routing electrical current
US20070021803A1 (en) 2005-07-22 2007-01-25 The Foundry Inc. Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction
US7917227B2 (en) 2005-10-03 2011-03-29 Standen Ltd. Optimizing characteristics of an electric field to increase the field's effect on proliferating cells
US8734438B2 (en) 2005-10-21 2014-05-27 Covidien Ag Circuit and method for reducing stored energy in an electrosurgical generator
US7947039B2 (en) 2005-12-12 2011-05-24 Covidien Ag Laparoscopic apparatus for performing electrosurgical procedures
AU2006335194B2 (en) * 2006-01-03 2011-10-27 Alcon Inc. System for dissociation and removal of proteinaceous tissue
US8216223B2 (en) 2006-01-24 2012-07-10 Covidien Ag System and method for tissue sealing
US8147485B2 (en) 2006-01-24 2012-04-03 Covidien Ag System and method for tissue sealing
US9186200B2 (en) 2006-01-24 2015-11-17 Covidien Ag System and method for tissue sealing
US8685016B2 (en) 2006-01-24 2014-04-01 Covidien Ag System and method for tissue sealing
US7513896B2 (en) 2006-01-24 2009-04-07 Covidien Ag Dual synchro-resonant electrosurgical apparatus with bi-directional magnetic coupling
CA2574935A1 (en) 2006-01-24 2007-07-24 Sherwood Services Ag A method and system for controlling an output of a radio-frequency medical generator having an impedance based control algorithm
CA2574934C (en) 2006-01-24 2015-12-29 Sherwood Services Ag System and method for closed loop monitoring of monopolar electrosurgical apparatus
US7972328B2 (en) 2006-01-24 2011-07-05 Covidien Ag System and method for tissue sealing
US7651493B2 (en) 2006-03-03 2010-01-26 Covidien Ag System and method for controlling electrosurgical snares
US8019414B2 (en) * 2006-04-05 2011-09-13 Novocure Ltd. Treating cancer using electromagnetic fields in combination with other treatment regimens
US7651492B2 (en) 2006-04-24 2010-01-26 Covidien Ag Arc based adaptive control system for an electrosurgical unit
US7616980B2 (en) 2006-05-08 2009-11-10 Tyco Healthcare Group Lp Radial electrode array
US9913976B2 (en) 2006-06-19 2018-03-13 Highland Instruments, Inc. Systems and methods for stimulating and monitoring biological tissue
US9623241B2 (en) 2006-06-19 2017-04-18 Highland Instruments Treatment methods
WO2007149811A2 (en) 2006-06-19 2007-12-27 Highland Instruments, Inc. Apparatus and method for stimulation of biological tissue
US7722606B2 (en) * 2006-09-14 2010-05-25 LaZúre Technologies, LLC Device and method for destruction of cancer cells
US7794457B2 (en) 2006-09-28 2010-09-14 Covidien Ag Transformer for RF voltage sensing
US8483820B2 (en) * 2006-10-05 2013-07-09 Bioness Inc. System and method for percutaneous delivery of electrical stimulation to a target body tissue
US20080125771A1 (en) * 2006-11-27 2008-05-29 Michael Lau Methods and apparatuses for contouring tissue by selective application of energy
US8238996B2 (en) 2006-12-05 2012-08-07 Tyco Healthcare Group Lp Electrode array
EP3231480A1 (en) 2007-03-06 2017-10-18 Novocure Ltd. Treating cancer using electromagnetic fields in combination with photodynamic therapy
US8777941B2 (en) 2007-05-10 2014-07-15 Covidien Lp Adjustable impedance electrosurgical electrodes
US7834484B2 (en) 2007-07-16 2010-11-16 Tyco Healthcare Group Lp Connection cable and method for activating a voltage-controlled generator
JP5485153B2 (en) * 2007-08-14 2014-05-07 ノボキュア リミテッド Parasite treatment by electric field
JP5425077B2 (en) * 2007-08-23 2014-02-26 バイオネス インコーポレイテッド System for transmitting current to body tissue
US9757554B2 (en) 2007-08-23 2017-09-12 Bioness Inc. System for transmitting electrical current to a bodily tissue
US8738137B2 (en) 2007-08-23 2014-05-27 Bioness Inc. System for transmitting electrical current to a bodily tissue
US8216220B2 (en) 2007-09-07 2012-07-10 Tyco Healthcare Group Lp System and method for transmission of combined data stream
US8562602B2 (en) * 2007-09-14 2013-10-22 Lazure Technologies, Llc Multi-layer electrode ablation probe and related methods
CN101854977B (en) * 2007-09-14 2015-09-09 拉热尔技术有限公司 Prostate cancer ablation
WO2009036459A1 (en) * 2007-09-14 2009-03-19 Lazure Technologies, Llc Multi-tine probe and treatment by activation of opposing tines
US8512332B2 (en) 2007-09-21 2013-08-20 Covidien Lp Real-time arc control in electrosurgical generators
US8231618B2 (en) * 2007-11-05 2012-07-31 Stereotaxis, Inc. Magnetically guided energy delivery apparatus
US9707403B2 (en) 2007-12-12 2017-07-18 Neuro Code Tech Holdings, Llc Rapid destruction of malignant tumors by excitotoxicity and osmotic-shock medical tactics
US8620041B2 (en) * 2007-12-31 2013-12-31 Real Imaging Ltd. Method apparatus and system for analyzing thermal images
WO2009089517A1 (en) 2008-01-10 2009-07-16 The Neuro-Signaling Foundation Method and system for processing cancer cell electrical signals for medical therapy
WO2009118721A1 (en) 2008-03-28 2009-10-01 Real Imaging Ltd. Method apparatus and system for analyzing thermal images
JP4475343B2 (en) * 2008-04-04 2010-06-09 村田機械株式会社 E-mail gateway device
RU2010146628A (en) 2008-04-17 2012-05-27 Дзе Ньюро-Сигнэлинг Фаундейшн (Us) SYSTEM AND METHOD OF APOPTOSIS CHALLENGE IN MALIGNANT TUMOR CELLS FOR THE CONSERVATIVE TREATMENT
EP2291217A4 (en) * 2008-04-17 2012-01-11 Neuro Code Technologies Llc Hybrid scientific computer system for processing cancer cell signals as medical therapy
US8226639B2 (en) 2008-06-10 2012-07-24 Tyco Healthcare Group Lp System and method for output control of electrosurgical generator
US20090326602A1 (en) 2008-06-27 2009-12-31 Arkady Glukhovsky Treatment of indications using electrical stimulation
US20100100093A1 (en) * 2008-09-16 2010-04-22 Lazure Technologies, Llc. System and method for controlled tissue heating for destruction of cancerous cells
US8262652B2 (en) 2009-01-12 2012-09-11 Tyco Healthcare Group Lp Imaginary impedance process monitoring and intelligent shut-off
US8728139B2 (en) 2009-04-16 2014-05-20 Lazure Technologies, Llc System and method for energy delivery to a tissue using an electrode array
US20110118729A1 (en) * 2009-11-13 2011-05-19 Alcon Research, Ltd High-intensity pulsed electric field vitrectomy apparatus with load detection
US20110144562A1 (en) * 2009-12-14 2011-06-16 Alcon Research, Ltd. Localized Pharmacological Treatment of Ocular Tissue Using High-Intensity Pulsed Electrical Fields
US8882759B2 (en) 2009-12-18 2014-11-11 Covidien Lp Microwave ablation system with dielectric temperature probe
US8568404B2 (en) 2010-02-19 2013-10-29 Covidien Lp Bipolar electrode probe for ablation monitoring
US9526911B1 (en) 2010-04-27 2016-12-27 Lazure Scientific, Inc. Immune mediated cancer cell destruction, systems and methods
US8750986B2 (en) 2010-07-16 2014-06-10 Boston Scientific Neuromodulation Corporation System and method for estimating clustering of electrodes in neurostimulation system
US8700165B2 (en) * 2010-07-16 2014-04-15 Boston Scientific Neuromodulation Corporation System and method for estimating lead configuration from neighboring relationship between electrodes
US8546979B2 (en) 2010-08-11 2013-10-01 Alcon Research, Ltd. Self-matching pulse generator with adjustable pulse width and pulse frequency
WO2012054560A1 (en) 2010-10-21 2012-04-26 Highland Instruments, Inc. Methods for detecting a condition
WO2013105987A2 (en) 2011-02-15 2013-07-18 Hemosonics, Llc Characterization of blood hemostasis and oxygen transport parameters
US9033973B2 (en) 2011-08-30 2015-05-19 Covidien Lp System and method for DC tissue impedance sensing
CA2864468C (en) * 2012-02-13 2021-06-22 Gaby PELL Use of transcranial magnetic stimulation to modulate permeability of the blood-brain barrier
US9655669B2 (en) 2013-05-06 2017-05-23 Novocure Limited Optimizing treatment using TTFields by changing the frequency during the course of long term tumor treatment
US10779875B2 (en) 2013-05-06 2020-09-22 Novocure Gmbh Optimizing treatment using TTfields by changing the frequency during the course of long term tumor treatment
US9872719B2 (en) 2013-07-24 2018-01-23 Covidien Lp Systems and methods for generating electrosurgical energy using a multistage power converter
US9636165B2 (en) 2013-07-29 2017-05-02 Covidien Lp Systems and methods for measuring tissue impedance through an electrosurgical cable
US20190117963A1 (en) 2014-07-25 2019-04-25 Loyalty Based Innovations, LLC Apparatus and method for treating multiple tumors in patients with metastatic disease by electric fields
US9833617B2 (en) 2014-07-25 2017-12-05 Loyalty Based Innovations, LLC Apparatus and method for treating multiple tumors in patients with metastatic disease by electric fields
USD759803S1 (en) 2014-10-28 2016-06-21 Highland Instruments, Inc. Adjustable headpiece with anatomical markers
WO2016070013A1 (en) 2014-10-31 2016-05-06 Medtronic Advanced Energy Llc Fingerswitch circuitry to reduce rf leakage current
US9726647B2 (en) 2015-03-17 2017-08-08 Hemosonics, Llc Determining mechanical properties via ultrasound-induced resonance
US10278616B2 (en) 2015-05-12 2019-05-07 Navix International Limited Systems and methods for tracking an intrabody catheter
CN107635463B (en) 2015-05-12 2021-12-28 纳维斯国际有限公司 Contact quality assessment by dielectric property analysis
US10828106B2 (en) 2015-05-12 2020-11-10 Navix International Limited Fiducial marking for image-electromagnetic field registration
RU2017140235A (en) 2015-05-12 2019-06-13 Навикс Интернэшнл Лимитед Assessment of lesions by analyzing dielectric properties
US20160331263A1 (en) * 2015-05-13 2016-11-17 Ep Solutions Sa Customizable Electrophysiological Mapping Electrode Patch Systems, Devices, Components and Methods
US11154238B2 (en) 2015-08-07 2021-10-26 Electroceuticals, Llc Systems, methods and apparatuses for providing bioelectronic neurocode-based therapies to mammals
US10188851B2 (en) 2015-10-28 2019-01-29 Novocure Limited TTField treatment with optimization of electrode positions on the head based on MRI-based conductivity measurements
US20180001075A1 (en) * 2016-06-30 2018-01-04 Novocure Limited Arrays for Longitudinal Delivery of TTFields to a Body
US11350996B2 (en) 2016-07-14 2022-06-07 Navix International Limited Characteristic track catheter navigation
WO2018092063A1 (en) 2016-11-16 2018-05-24 Navix International Limited Real-time display of treatment-related tissue changes using virtual material
US11331029B2 (en) 2016-11-16 2022-05-17 Navix International Limited Esophagus position detection by electrical mapping
EP3541313B1 (en) 2016-11-16 2023-05-10 Navix International Limited Estimators for ablation effectiveness
CN110177500B (en) 2016-11-16 2022-03-04 纳维斯国际有限公司 Dynamic visual rendering of tissue models
WO2018092062A1 (en) 2016-11-16 2018-05-24 Navix International Limited Real-time display of tissue deformation by interactions with an intra-body probe
US20190117970A1 (en) * 2017-10-23 2019-04-25 Cardiac Pacemakers, Inc. Electric field shaping leads for treatment of cancer
US11338135B2 (en) 2017-10-23 2022-05-24 Cardiac Pacemakers, Inc. Medical devices for cancer therapy with electric field shaping elements
US10953209B2 (en) 2018-03-28 2021-03-23 Board Of Regents Of The University Of Texas System Treating tumors using TTFields combined with a PARP inhibitor
US11298422B2 (en) 2018-04-09 2022-04-12 Novocure Gmbh Treating tumors with TTFields and an aurora kinase inhibitor
PL3775956T3 (en) 2018-04-10 2022-10-10 Novocure Gmbh Low frequency (< 1 mhz) ac conductivity estimates derived from two mri images having different repetition times
CN116173401A (en) 2018-07-03 2023-05-30 埃德温·阊 Enhancement of cell membrane permeability using alternating electric fields
WO2020009306A1 (en) * 2018-07-03 2020-01-09 고려대학교 산학협력단 Electric field cancer treatment device and method using optimization algorithm
KR102104961B1 (en) * 2018-07-03 2020-04-27 고려대학교산학협력단 Apparatus for alternating electric fields therapy using optimized algorithm
US11179322B2 (en) 2018-07-10 2021-11-23 Novocure Gmbh Methods and compositions for treating tumors with TTFields and sorafenib
WO2020012364A1 (en) 2018-07-10 2020-01-16 Novocure Gmbh Inhibiting viral infection using alternating electric fields
MX2020013431A (en) 2018-07-18 2021-05-27 Novocure Gmbh Using power loss density and related measures to quantify the dose of tumor treating fields (ttfields).
US11351349B2 (en) 2018-08-23 2022-06-07 Novocure Gmbh Using alternating electric fields to increase permeability of the blood brain barrier
US11623085B2 (en) * 2018-08-29 2023-04-11 Regents Of The University Of Minnesota Devices and methods for treatment of tumors using electromagnetic signal
US11160977B2 (en) 2018-09-04 2021-11-02 Novocure Gmbh Delivering tumor treating fields (TTFields) to the infratentorial brain
CN112770806A (en) 2018-09-07 2021-05-07 诺沃库勒有限责任公司 Treatment of autoimmune diseases using alternating electric fields to reduce proliferation of T cells
EP3840823B1 (en) 2018-10-15 2023-07-12 Novocure GmbH Generating tumor treating fields (ttfields) with high uniformity throughout the brain
JP7148722B2 (en) * 2018-10-25 2022-10-05 ゼーヴ・ボンゾン Delivery of an alternating electric field (e.g., TTField) to the spinal structures of a subject
EP3922301B1 (en) 2018-11-19 2024-02-21 Novocure GmbH Arrays for delivering tumor treating fields (ttfields) with selectively addressable sub-elements
KR102606263B1 (en) 2018-11-29 2023-11-23 노보큐어 게엠베하 Enhanced Flexible Transducer Arrays Delivering Tumor Treatment Fields
CN113766949A (en) 2019-04-22 2021-12-07 波士顿科学国际有限公司 System for applying electrical stimulation to treat cancer
JP2022530872A (en) 2019-04-22 2022-07-04 ボストン サイエンティフィック サイムド,インコーポレイテッド Electrical stimulation device for cancer treatment
US11607542B2 (en) 2019-04-23 2023-03-21 Boston Scientific Scimed, Inc. Electrical stimulation for cancer treatment with internal and external electrodes
EP3958960A1 (en) 2019-04-23 2022-03-02 Boston Scientific Scimed Inc. Electrical stimulation with thermal treatment or thermal monitoring
CN113747936A (en) 2019-04-23 2021-12-03 波士顿科学国际有限公司 Electrode for electrical stimulation to treat cancer
US11941761B2 (en) 2019-12-31 2024-03-26 Novocure Gmbh Methods, systems, and apparatuses for image segmentation
BR112022012431A2 (en) 2019-12-31 2022-08-30 Novocure Gmbh HIGH VOLTAGE AND HIGH EFFICIENCY SINE WAVE GENERATOR THAT AVOIDS Surges DURING AMPLITUDE ADJUSTMENTS AND CHANNEL SWITCHING
US11878163B2 (en) 2019-12-31 2024-01-23 Novocure Gmbh Arrays for delivering tumor treating fields (TTFields) with individually accessible electrode elements and temperature sensors
WO2021173509A1 (en) 2020-02-24 2021-09-02 Boston Scientific Scimed, Inc. Systems and methods for treatment of pancreatic cancer
KR102644003B1 (en) * 2020-04-01 2024-03-07 한국전자통신연구원 Cancer treatment device
TW202200232A (en) * 2020-05-06 2022-01-01 瑞士商諾沃庫勒有限責任公司 Conductive pad generating tumor treating field and methods of production and use thereof
EP4168108A1 (en) 2020-06-19 2023-04-26 The Methodist Hospital dba Houston Methodist Hospital Method and apparatus for oncomagnetic treatment
US11818943B2 (en) 2020-06-25 2023-11-14 Novocure Gmbh Fabricating organic light emitting diodes (OLEDs) using tubulin
KR102490645B1 (en) * 2020-07-16 2023-01-25 고려대학교 산학협력단 System and Method for Planning Electric Fields Therapy based on Absorbed Energy
KR20230073173A (en) 2020-09-25 2023-05-25 노보큐어 게엠베하 Changing the metallization area of individual electrode elements in the Tumor Therapy Field (TTFIELDS) system to maximize current without overheating
KR102556846B1 (en) * 2020-10-26 2023-07-18 주식회사 뉴아인 Device that induces destroying cells on abnormally dividing cells and the driving method thereof
CN113350689A (en) * 2021-06-08 2021-09-07 湖南安泰康成生物科技有限公司 Equipment for inhibiting tumor proliferation by using electric field and detection method and device thereof
CN113577562A (en) * 2021-07-26 2021-11-02 昆仑智鼎(北京)医疗技术有限公司 Alternating electric field device for selectively destroying or inhibiting mitosis of tumor cells
CN113521541A (en) * 2021-07-26 2021-10-22 昆仑智鼎(北京)医疗技术有限公司 Device for selectively disrupting or inhibiting mitosis of tumor cells
US20230098801A1 (en) * 2021-09-30 2023-03-30 Novocure Gmbh Reducing Electrosensation Whilst Treating A Subject Using Alternating Electric Fields
CN117563139B (en) * 2024-01-12 2024-04-09 湖南安泰康成生物科技有限公司 Device and processor for inhibiting tumor proliferation by using electric field

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR446660A (en) 1911-09-02 1912-12-12 Gottlieb Schuettel Device for continuous ring looms for mounting the sliders on the rings
US4016886A (en) 1974-11-26 1977-04-12 The United States Of America As Represented By The United States Energy Research And Development Administration Method for localizing heating in tumor tissue
US4121592A (en) 1975-08-04 1978-10-24 Critical Systems, Inc. Apparatus for heating tissue
US4121506A (en) * 1977-03-23 1978-10-24 The Continental Group, Inc. Carton forming apparatus
DE2813068A1 (en) 1978-03-25 1979-10-04 Philips Patentverwaltung METHOD AND DEVICE FOR DETERMINING INTERNAL BODY STRUCTURES
US4472506A (en) 1981-01-13 1984-09-18 Liburdy Robert P Method for determining cell membrane dielectric breakdown
US4467809A (en) 1982-09-17 1984-08-28 Biolectron, Inc. Method for non-invasive electrical stimulation of epiphyseal plate growth
US4622952A (en) 1983-01-13 1986-11-18 Gordon Robert T Cancer treatment method
CA1244889A (en) 1983-01-24 1988-11-15 Kureha Chemical Ind Co Ltd Device for hyperthermia
DE3323415C2 (en) 1983-06-29 1985-04-25 Kernforschungsanlage Jülich GmbH, 5170 Jülich Use of a method and a device for the determination of cells secreting cell constituents
SE455920B (en) 1986-01-29 1988-08-22 Hans Wiksell TUMOR HYPERTERMY TREATMENT DEVICE
US4923814A (en) 1986-05-09 1990-05-08 Electropore, Inc. High speed, high power apparatus for vesicle prealignment, poration, loading and fusion in uniform electric fields and method therefor
US4822470A (en) 1987-10-09 1989-04-18 Baylor College Of Medicine Method of and apparatus for cell poration and cell fusion using radiofrequency electrical pulses
US4936303A (en) 1987-11-20 1990-06-26 Ultrathermics Ultrasonic heating apparatus and method
JPH0629196B2 (en) 1987-12-01 1994-04-20 甲子郎 梅村 Physiological action enhancer for tumor treatment by ultrasound
US5389069A (en) 1988-01-21 1995-02-14 Massachusetts Institute Of Technology Method and apparatus for in vivo electroporation of remote cells and tissue
FR2627987B3 (en) 1988-03-04 1990-02-02 Indiba Sa ELECTRONIC APPARATUS FOR MEDICAL AND COSMETIC THERAPY
US5158071A (en) 1988-07-01 1992-10-27 Hitachi, Ltd. Ultrasonic apparatus for therapeutical use
US5099756A (en) 1989-06-01 1992-03-31 Harry H. Leveen Radio frequency thermotherapy
US5441746A (en) 1989-12-22 1995-08-15 Molecular Bioquest, Inc. Electromagnetic wave absorbing, surface modified magnetic particles for use in medical applications, and their method of production
US5236410A (en) 1990-08-02 1993-08-17 Ferrotherm International, Inc. Tumor treatment method
CA2109084C (en) 1991-05-03 2004-02-24 John William Fisher Costerton Biofilm reduction method
US5441532A (en) 1991-06-26 1995-08-15 Massachusetts Institute Of Technology Adaptive focusing and nulling hyperthermia annular and monopole phased array applicators
US5468223A (en) 1992-11-30 1995-11-21 C.N.R.S. Paris Electrochemotherapy
US5386837A (en) 1993-02-01 1995-02-07 Mmtc, Inc. Method for enhancing delivery of chemotherapy employing high-frequency force fields
FR2703253B1 (en) 1993-03-30 1995-06-23 Centre Nat Rech Scient APPLICATOR OF ELECTRIC PULSES FOR TREATING BIOLOGICAL TISSUES.
US5704355A (en) 1994-07-01 1998-01-06 Bridges; Jack E. Non-invasive system for breast cancer detection
AU6639596A (en) 1995-07-28 1997-02-26 James R. Gray Use of a polarizing field to modify the efficacy of a bioactive agent
US5606971A (en) 1995-11-13 1997-03-04 Artann Corporation, A Nj Corp. Method and device for shear wave elasticity imaging
US5718246A (en) 1996-01-03 1998-02-17 Preferential, Inc. Preferential induction of electrically mediated cell death from applied pulses
US5984882A (en) 1996-08-19 1999-11-16 Angiosonics Inc. Methods for prevention and treatment of cancer and other proliferative diseases with ultrasonic energy
US5869326A (en) 1996-09-09 1999-02-09 Genetronics, Inc. Electroporation employing user-configured pulsing scheme
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
WO1999011771A1 (en) 1997-09-04 1999-03-11 Science Research Laboratory, Inc. Cell separation using electric fields
US6027488A (en) 1998-06-03 2000-02-22 Genetronics, Inc. Flow-through electroporation system for ex vivo gene therapy
US5976092A (en) 1998-06-15 1999-11-02 Chinn; Douglas O. Combination stereotactic surgical guide and ultrasonic probe
US6319901B1 (en) 1998-10-15 2001-11-20 Ichor Medical Systems, Inc. Methods for prolonging cell membrane permeability
EP1158919B1 (en) 1999-03-09 2005-06-29 Thermage, Inc. Apparatus for treatment of tissue
US6366808B1 (en) 2000-03-13 2002-04-02 Edward A. Schroeppel Implantable device and method for the electrical treatment of cancer
US6853864B2 (en) * 2000-02-02 2005-02-08 Catholic University Of America, The Use of electromagnetic fields in cancer and other therapies
US7136699B2 (en) 2002-10-02 2006-11-14 Standen, Ltd. Apparatus for destroying dividing cells
US7089054B2 (en) 2002-10-02 2006-08-08 Standen Ltd. Apparatus and method for treating a tumor or the like
US7016725B2 (en) 2001-11-06 2006-03-21 Standen Ltd. Method and apparatus for destroying dividing cells
EP2335776A1 (en) 2000-02-17 2011-06-22 Yoram Palti Method and apparatus for destroying dividing cells
US20030060866A1 (en) 2001-09-25 2003-03-27 Schmidt John A. Multi-electrode stimulation parallel to cardiac myofibers

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10792495B2 (en) 2016-12-01 2020-10-06 Thimble Bioelectronics, Inc. Neuromodulation device and method for use
US11801383B2 (en) 2016-12-01 2023-10-31 Hinge Health, Inc. Neuromodulation device and method for use

Also Published As

Publication number Publication date
US7146210B2 (en) 2006-12-05
US20040176804A1 (en) 2004-09-09

Similar Documents

Publication Publication Date Title
US7146210B2 (en) Apparatus and method for optimizing tumor treatment efficiency by electric fields
CA2563817C (en) Treating a tumor or the like with electric fields at different frequencies
US6868289B2 (en) Apparatus for treating a tumor or the like and articles incorporating the apparatus for treatment of the tumor
US7089054B2 (en) Apparatus and method for treating a tumor or the like

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase